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ABSTRACT 
The goal of this dissertation is to expand our understanding of how influenza (flu) infection 
negatively impacts skeletal muscle and leads to future disability with aging. We hypothesize that 
flu infection triggers prolonged inflammation and increased immune cell presence in skeletal 
muscle leading to skeletal muscle atrophy and impaired muscle function accompanied by 
diminished regenerative capacity in aged mice. We first determined that despite lack of direct flu 
infection, flu led to skeletal muscle atrophic gene expression and impaired muscle function 
which was prolonged and heightened in aged mice (Chapter 2). Next, we determined that 
muscle atrophy primarily occurs in MyHC type IIB muscle fibers (Chapter 3). This occurred 
concomitantly with disrupted architecture, fibrosis, and increased nuclei in aged muscle IHC 
staining. Importantly, protective immunity via vaccination mitigated these effects. These studies 
culminated into a hypothesis generating transcriptomic project, which has painted a fully 
unbiased look into aged muscle processes during flu infection (Chapter 4). Interestingly, these 
experiments point to an immune-mediated, primarily T cell, driven myopathy during flu infection 
in aged muscle. The studies in this thesis are the first to examine in depth how flu impacts 
skeletal muscle with aging and leads to muscle dysfunction and disability. While many questions 
remain, this research has laid the ground work for others to test pathways/genes as 
mechanism(s) of flu-induced muscle atrophy with aging as the first step of developing 
prevention and treatment options. Indeed, development of prophylactic and therapeutic 
treatments for flu-induced myopathies could save lives of countless older adults, prevent 
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Influenza and Older Adults 
Influenza viruses belong to the Orthomyxoviridae family and are enveloped, negative-sense, 
single-stranded RNA viruses with segmented genomes [1]. Influenza A is most often associated 
with human illness with H1N1 subtypes more often resulting in milder illness when compared to 
H3N2 subtypes, which are responsible for 80% of flu-related deaths [2]. Rapid mutations leave 
us with an ineradicable disease that has frequent epidemics. Although most influenza virus 
infections result in an acute, self-limiting illness, severe and fatal infections are associated with 
hemorrhagic bronchitis, bronchiolitis, and alveolitis with pulmonary edema and hemorrhage [3]. 
There are also several comorbidities that increase vulnerability to influenza infection, including 
underlying chronic respiratory and cardiovascular conditions, diabetes mellitus and 
immunosuppression [4, 5]. Immunocompromised individuals also have increased risk of 
enhanced disease after flu infection with prolonged viral shedding that can last for months [6]. 
There are severe age-related immune declines that lead to increased susceptibility and severity 
of flu infection in older adults.  Additionally, older individuals often experience fewer clinical 
signs and symptoms of classical influenza infection, while also experiencing more severe 
complications of the disease [4-6].  
It is well established that immune function declines with aging. Age-related declines of both the 
innate and adaptive immune systems result in increased susceptibility to infection, as well as 
increased severity of infection in older adults [7, 8]. Influenza (flu) is problematic in older adults 
with increased risk for serious complications and hospitalization. In addition, approximately 90% 
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of flu-related deaths occur in this population [9], with influenza and pneumonia being the eighth 
leading cause of death among persons over 65 years of age in the United States [10]. Even 
when death is avoided, older adults have an increased risk for secondary complications and 
morbidities from flu infection. The average annual infection rate of seasonal flu is 10-20 percent 
of the world population with 3-5 million hospitalizations and estimated United States economic 
burden of $87.1 billion USD [11, 12].  
Flu infections in older adults often cause hospitalization due to prolonged illness and secondary 
infections, such as bacterial pneumonia. Hospitalizations attributable to flu vary depending on 
the flu season length and circulating strains [2]. Multiple models demonstrate a common trend 
for increased flu-related mortality over the past 30 years [13, 14], seemingly parallel to the 
increased older adult population and the growing aged population is at greatest risk. The 
mortality rate for adults over 85 is 16x greater than individuals 65-69 years of age [2]. 
Additionally, the average length of a hospital stay for flu-related complications is 2 days longer 
in patients over 75 compared to adults 50-64 years of age [2]. 
In addition to common flu symptoms, flu infection leaves older adults more susceptible to 
secondary infection and causes dysfunction in many other tissues. These complications are 
often both caused by and lead to other co-morbidities, which increases mortalities.  For 
example, secondary bacterial infection following flu is responsible for five million cases of 
severe illness, which results in 250,000-500,000 deaths worldwide. Recently, these have been 
categorized together by the CDC as influenza/pneumonia deaths [14, 15]. Due to both 
immunosenescence and overall senescence that occurs with aging, the body is more prone to 
complications resulting from delayed and weakened responses to maintain homeostatic 
function. Extrapulmonary and other complications in older adults can include cardiovascular 
dysfunction, musculoskeletal atrophy, neurological degeneration, and worsening of preexisting 
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diseases. Importantly, many of these effects may be delayed so the association with flu infection 
may be initially masked. 
Age-related declines in immune responses have been well-documented in both murine and 
human systems. Here, we will briefly review age-related immune changes and how they relate 
to the impaired response to flu infection, focusing more on the clinical significance of common 
and uncommon flu-associated complications in older adults. Identifying mechanisms of common 
and uncommon flu-associated complications in older adults can provide initial insight for future 
therapeutic investigations to enhance age-related immune declines and determine effective 
ways to prevent flu-related morbidity and mortalities.  
 
Age-related immune deficits 
The overall aging process leads to a decreased ability to respond to stressors and maintain 
homeostasis. Commonly, murine models of aging are utilized to investigate age-related 
changes in the immune system and the C57BL/6 mouse is considered to be one of the most 
studied animal models. Indeed, this mouse shares many important processes with the human 
immune system and in aging biology (Figure 1 [1-16]). Briefly, during the biological process of 
aging many immune system components are impacted. Age-related DNA damage in the bone 
marrow is associated with increased release of immature cells into the blood and a bias for 
differentiation toward myeloid lineage cells over lymphoid lineage cells from hematopoietic stem 
cells [22, 39, 1640, 41]. The innate immune system (specifically neutrophils, macrophages, and 
dendritic cells [DCs]) exhibits decreased migration and chemotaxis [29, 31, 37, 42], as well as 
decreased phagocytosis [33, 36, 39, 42, 46] and changes in population frequencies [28, 39, 40, 
59] in both aging humans and mice. Similarly, the adaptive immune system exhibits decreased 
function with aging. In both mice and humans, thymic involution and dysfunction lead to 
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decreased naïve T cell output with aging [58, 60]. In addition,  T cell function and memory T cell 
generation are negatively impacted by aging [18, 19, 27, 30, 64, 65, 69] and antibody quality is 
also reduced [77, 78]. In summary, the aged immune systems of both humans and mice exhibit 
delayed and reduced responsiveness with regards to both innate and adaptive aspects resulting 
in an overall poor response to an infectious challenge.  
 
Figure 1. Summary of age-related changes to the immune systems of humans and mice [11-76]. 
Increases or decreases in cell numbers or particular functions are indicated by arrows pointing upward or 
downward. Figure made with biorender.com. 
 
Impact of aging on immune responses to influenza 
Along with immunosenescence, or the deleterious age-associated changes in immunity 
described above [81], “inflammaging” leads to cytokine imbalance, tipping towards constant 
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inflammation both within tissues and systemically. Indeed, immunosenescence and 
inflammaging play a large role in exacerbating flu infection in older adults. Immunosenescence 
is associated with decreased phagocyte function, altered cellular migration, changes in cell 
population numbers, and reduced antibody production [45]. Further, we would expect the same 
trends during flu infection, which would impair adaptive immunity and hinder the immune 
responsiveness to infection.  
Innate immune cells, specifically DCs, produce less interferon I/III in older adults, while showing 
decreasing phagocytic capacity [82]. Further, phagocytes and DCs have altered receptor signal 
transduction and systemic over population of neutrophils (neutrophilia) in older adults can 
promote increased serum levels of IL-6 and c-reactive protein that increases death risk [82]. 
Larger issues arise during a secondary infection (bacterial or viral) since the increased 
inflammatory/infection damage leaves the system both frail and exhausted [82]. DCs play a 
large role in generating innate and adaptive immune responses, but aged mouse studies have 
observed that the number of DCs recovered from spleens of aged mice is 50-70% of that found 
in young mice during flu infection [83]. Further studies indicated that during flu infection, DCs in 
aged mice had significant differences in maturation, migration, and recruitment [83-86], as well 
as low expression of the co-stimulatory molecules CD40 and CD86 [87]. 
Age-related declines in immune function contribute significantly and lead to multiple 
manifestations with regards to the CD4 T cell response to flu antigens [88]. Importantly, the 
proper functioning of CD4 T cells is essential for a robust CD8 T cell response to flu infection. 
Changes in T cell responses during flu infection with aging include impaired T cell receptor 
signaling via reduced immunological synapse formation [88-90] and deficits in CD4 T cell 
activation, differentiation, and proliferation [19]. With aging there is also an increase in FoxP3+ 
regulatory CD4 T cells (Tregs), which produce anti-inflammatory molecules, resulting in reduced 
expression of co-stimulatory molecules CD40 and CD86 [87].  
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CD8 T cells are indispensable for clearance of flu infected cells. Influenza virus-specific CD8 T 
cells from older adults exhibit decreased functionality with corresponding increases in CD57 and 
KLRG1 expression, indicating a senescent phenotype [91]. These same CD8 T cells also have 
reduced expression of inhibitory receptors such as PD-1, resulting in higher frequencies of flu-
specific CD8 T cells that exhibit reduced lytic capacity and decreased migration and chemotaxis 
ability during flu infection. The overall result of these age-related changes is slower viral 
clearance [83, 92]. Increasing age also has a significant impact on the memory CD8 T cell 
response to flu infection due to the loss of protective effector memory cells from peripheral 
tissues over time [93, 94, 95].  
Similarly, aging impacts B cell and antibody responses to flu infection. Declines in B cell 
precursors in old age are associated with preferential loss of lymphoid-biased hematopoietic 
stem cells [58]. With aging, there is decreased germinal center formation during flu infection and 
B cells produce lower quality antibody [77,78] in both humans and mice [77]. In addition, the 
increase in senescent B cells with aging is negatively associated with a protective response 
following flu vaccination. Importantly, many of these age-related declines in humoral responses 
following influenza infection and vaccination are partially due to declines in CD4 T cell function 
with aging [20, 71].  
Related to these immune cell specific alterations, lymph node stromal cells and particularly 
fibroblastic reticular cells, are impacted by aging. Lymph node fibroblastic reticular cells are not 
significantly different between young and aged mice at steady state but have delayed 
proliferation and expansion in aged mediastinal lymph nodes during flu infection [96]. Further, in 
aged lymph nodes, mouse fibroblastic reticular cells exhibit notably reduced homeostatic 
chemokine production, which is associated with reduced T cell homing to these lymph nodes 
during flu infection. Ultimately, this is associated with delayed and impaired immune responses 
in aged mice [96].  
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Another factor to be considered regarding the immune response to flu infection is the gut 
microbiota, which is also important in regulating immune responses both locally and 
systemically [97]. Pulmonary immunity is directly related to gut microbiota, which mediates flu 
infection-related responses, including dendritic cell migration, T cell priming, cytokine secretion, 
and overall viral clearance [98]. Dysbiosis of the gut microbiota induced by antibiotic 
administration during flu infection influences helper T cell responses and can negatively impact 
flu outcomes and recovery [99]. This is of particular interest with aging, as older adults are more 
likely to have concurrent infections and may be on antibiotics at the time of flu infection itself or 
due to a secondary infection. Adequate probiotic intervention after antibiotic treatment may 
improve the intestinal ecosystem and prevent Th2-shifted immunity [100]. Indeed, without 
probiotic treatment there is further dysregulation of cytokines and cell mediated regeneration 




Figure 2. Influenza infection of the upper respiratory tract leads to complications in other tissues 
and organs. These complications are made worse by the diminished immune response in older adults. 
Figure made with biorender.com. 
 
Common complications in older adults 
Influenza infection of the upper respiratory tract leads to complications in other tissues and 
organs (see Figure 2). These complications are made worse by the diminished immune 
response in older adults. In this section, we will describe the common complications seen in 




Secondary bacterial infections 
The most frequent concurrent bacterial infections with flu are pneumopathogens: 
Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus 
influenzae, and occasionally other gram-negative bacilli [101, 102]. Opportunistic bacterial 
infections, which are common in older adults, occur during and post influenza through many 
mechanisms. For example, necrosis of airway epithelial cells can result in loss of mucociliary 
clearance, which then leads to increased colonization of the upper respiratory tract due to loss 
of physical barriers [103]. In fact, exposure of bacterial attachment sites can result from 
damaged surfaces of airways with associated fibrin deposition, tissue repair, regenerative 
process, and sialidase activity of the viral neuraminidase [104, 105]. Similar to humans, mice 
infected with flu have suppressed Th17 responses and macrophage function leading to inhibited 
NADPH-oxidase-dependent phagocytic bacterial clearance [106,107].  
Secondary bacterial infection can cause physical damage resulting in blockage or small airway 
functional loss from cellular debris. Additionally, proteinaceous edema fluid and development of 
exudative transmural pleuritis can severely compromise the respiratory system [108, 109]. In 
older adults, there is a loss of respiratory epithelial progenitor basal cells resulting in epithelial 
cell damage, bacterial invasion and decreased lung repair [80]. During enhanced disease states 
the generation of a robust inflammatory response can lead to subsequent increase in anti-
inflammatory responses, which restricts adaptive immune responses [110, 111]. Human studies 
examining the effects of the immunosuppressive cytokine interleukin (IL)-10 demonstrate that 
the ratio of interferon gamma to IL-10 (IFN-γ:IL-10) produced by ex vivo stimulation with flu virus 
and IL-7 of peripheral blood T cells is reduced in old age due to increases in IL-10 production 
[112] and this significantly correlates with patients suffering from laboratory diagnosed flu 
infection [113]. These studies also associated high IL-10 in the blood with increased longevity, 
but also greater susceptibility to flu infection in older adults. Thus, IL-10 seems to be important 
10 
 
in longevity to control overall age-related inflammation, but it can also have a negative impact 
on the adaptive immune response to infection, leaving older individuals more susceptible to 
severe infection.  
Conversely, lack of control of proinflammatory cytokines can also aggravate disease in older 
adults and has been described in cases of flu and Streptococcus pneumoniae [114]. In some 
cases, there has been strong evidence of excessive neutrophil infiltration and early mortality 
[114]. In aged mice, susceptibility to S. pneumoniae infection was correlated with increased 
systemic proinflammatory cytokines, including TNF-α, prior to S. pneumoniae infection [114].  
Indeed, we and others have shown that old mice have a prolonged and elevated inflammatory 
response following flu infection [24, 96, 115, 116, 117].   
In summary, bacterial infection following flu leads to weakened lung efficiency, blood 
oxygenation, and multiple organ system disfunction. In fact, hospitalizations and mortality 
resulting from flu infections are most commonly due to these complications, rather than the flu 
infection itself.  
 
Acute Respiratory Distress Syndrome 
In addition to secondary bacterial infections, acute respiratory distress syndrome (ARDS) is 
another common complication of flu infection, especially in the context of human aging [118, 
119, 120]. ARDS is severe respiratory failure characterized by diffuse inflammation of alveolar 
and vascular lung structures which produces progressive hypoxemia [121]. ARDS is associated 
with the rapid onset of cyanosis, delirium, incontinence, and lungs filled with frothy blood-tinged 
sputum, all of which can be attributed to primary viral flu pneumonia [122, 123]. The rapid 
progression from viral pneumonia to ARDS in previously healthy adults suggests that the body’s 
reaction to infection leads to advanced disease states rather than flu-associated damage [124].  
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When combined with flu infection, ARDS can be devastating and can often result in death. In an 
ARDS study independent of flu, patients had a 67% survival rate at 5 years post hospital 
discharge and suffered decreased physical quality of life, increased costs and use of health care 
services, and irrecoverable severe lung injury [125, 126]. The H1N1 pandemic of 2009 caused 
severe hypoxemic respiratory failure defined as ARDS, independent of bacterial infection, but 
still with multi-organ involvement [127, 128]. Heart failure independent of myocarditis can also 
occur during flu infection and has higher prevalence in ARDS patients when compared to the 
general population [129]. In theory, older adults would not have the stem cell potential to repair 
the hypoxemic damage from this advanced disease nor the efficiency to clear damage quickly. 
Indeed, ARDS following flu leads to weakened lung efficiency, blood oxygenation, and disrupts 
multiple organ systems. 
 
Extrapulmonary and other uncommon complications in older adults 
In this section, we will examine the extrapulmonary and uncommon complications of flu infection 
in older adults (see Figure 2). These complications are often overlooked due to the distal nature 
from the primary site of infection and often times delayed onset.  
 
Cardiac Complications 
Cardiovascular complications during influenza infection are common in older adults. 
Myocarditis, defined as inflammation of the heart muscle affecting its ability to pump blood, is 
diagnosed with documented flu infection in 0.4-13% of cases, varying on the flu season [130, 
131]. Cellular infiltration and myocyte necrosis have been found in 30-50% of flu and flu-related 
deaths at autopsy, despite no previous cardiac complications or involvement [132, 133, 134]. 
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Further, myocarditis was not dependent on secondary pneumonia or other infections and was 
evident in cases of flu infection alone [135]. Age-related concerns arose when 69% of fatal 
cases, with both bacterial pneumonia and cardiac complications present post-flu, were in those 
over 18 years of age [132]. During the influenza A H1N1 pandemic of 2009, 70% (31/44) of 
studied patients with myocarditis were flu-related and, interestingly, only 32% were in people 
over 40 years of age [130, 131, 132, 133, 134, 135].  
Ischemic heart disease (IHD), defined as the narrowing of the heart arteries, is also associated 
with flu infection and believed to stem from inflammation that plays a critical role in acute 
coronary syndrome [136]. This stems from systemic pro-inflammatory responses triggered by flu 
infection that are coupled with pro-coagulant effects [137]. No human study or autopsy results 
currently suggest the theory of direct virus invasion of the vascular bed. In rare cases, viremia in 
pandemic influenza strains has occurred [138, 139], but not typically in most patients [140]. In a 
mouse model of atherosclerosis, mice over 24 months of age with this condition and flu infection 
develop more prominent inflammatory and thrombotic effects on atherosclerotic plaques, with 
subendothelial and smooth muscle immune infiltration [141]. This suggests that older adults with 
atherosclerosis are at greater risk for increased severity of flu infection and potential cardiac 
complications. 
Similar to ischemic heart disease are ischemic cerebral vascular accidents (CVAs), which also 
significantly increase in incidence after respiratory tract infection [142]. A study of adults (>18 
years) found transient increases in adverse vascular events following an acute flu infection, 
wherein the median age at myocardial infarction was 72.3 years of age and the median age at 
first stroke following acute flu infection was 78.3 years of age [142]. Thus, suggesting an age-
related at-risk population even though the direct link between flu infection and stroke events is 
unclear. A common theory is that increased damage and clotting factors in the blood during 
infection leads to greater risks of clotting in the arteries and the brain. Notably, reduced levels of 
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these clotting factors and reduced stroke incidence are present in vaccinated patients with most 
significant vaccine effects in men >65 years [143]. Similarly, in patients treated with oseltamivir, 
a common flu anti-viral, there is a 34% stroke risk reduction after 6 months in patients <65 years 
[144]. Interestingly, those who get an annual flu vaccine have a lesser likelihood of cardiac 
complications [145-147] and the largest treatment effect was seen among the highest risk 
patients (>65 years), with more active coronary disease. Indeed, vaccinated older adults were at 
a 2.9% risk for composite cardiovascular events versus 4.7% in those who were unvaccinated in 
a recent meta-analysis [145].  
 
Musculoskeletal 
Primary flu infection is limited to pulmonary epithelial cells, yet myalgias are a common 
symptom and older adults have increased risk for physical disability following flu infection. 
Skeletal muscle wasting in patients with lung diseases, including COPD, acute respiratory 
distress syndrome, and cystic fibrosis, contributes to worse outcomes and is associated with 
increased morbidity following flu infection [148]. Diaphragm dysfunction has also been reported 
in patients during flu infection and other related lung complications [149-151]. Importantly, 
skeletal muscle dysfunction plays a role in the pathophysiology of ARDS and is associated with 
prolonged mechanical ventilation, weaning failure (atrophy), and markedly elevated risk of 
returning to ICU post discharge. The median age of patients with ARDS who survived to be 
discharged from the ICU was 45 years (n=117) and the median age of those who died in ICU 
was 50 years (n = 78) [125]. This results in a vicious cycle of increased hospitalization and 
impaired quality of life associated with greater morbidity and mortality [126, 152]. These studies 
found age was significantly associated with physical performance post ARDS hospital 
discharge, in those >52 years [126]. In fact, critically ill patients with ARDS from flu exhibit 
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weakness, fatigue, reduced exercise capacity, and lose muscle mass even after ICU discharge 
and after lung recovery [125]. 
Interestingly, skeletal muscle more distal to the site of infection also is affected by flu infection. 
Despite the fact that cases of viremia are rare and direct skeletal muscle infection does not 
occur in influenza [153-155], the clinical association of flu infection and disability with aging has 
been repeatedly shown especially in those >65 years of age [156-158]. Indeed, following flu 
infection older adults (>65 years) are at increased risk to lose activities of daily living and 
develop disabilities [158, 159]. Our laboratory was the first to demonstrate a molecular link for 
this interaction by characterizing the impact of flu infection on muscle health in mice. Overall, flu 
leads to mobility impairments with induction of inflammatory and muscle degradation genes and 
downregulation of positive regulators of muscle growth. These effects are prolonged with aging 
(mice >21 months), suggesting a direct link between flu infection and increased risk of disability 
in older adults [115]. Others demonstrated  in adult (12-16 week) mice that muscle wasting 
during/post flu infections is through IL-6 regulation of the E3 ubiquitin ligase atrogin-1 pathway 
[160], further supporting increased risk with aging as IL-6 is already implicated in aging.  
In more serious situations, though much less common, extreme muscle wasting during flu 
infection has resulted in rhabdomyolysis, where extreme muscle breakdown causes leaking of 
muscle components into the blood stream that can lead to renal failure [155, 161-173]. Myositis 
and rhabdomyolysis have been reported during influenza A & B infection [168]. Additionally, a 
higher incidence of myositis has been observed in older adults (observed cases in 70-86 year 
patients) [169]. About 50% of adult patients hospitalized with influenza A had elevated serum 
creatine phosphokinase (CK), an indicator of muscle damage that can potentially lead to renal 
failure [174]. Between a quarter and half of people older than 85 years are estimated to be frail 
[175]. Frailty has also been associated with both an impaired antibody response to influenza 
and increased sarcopenia following flu infection [175]. Loss of muscle integrity and function is 
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clinically important, since flu infection has been associated with a greater incidence of falls in 
men and women over 70 years [176, 177]. A clinical study of 650 adults with confirmed flu 
cases and a mean age of 63 reported that two thirds of the subjects were at risk for flu-related 
morbidity and self-reported disability related to muscle pain/fatigue around 20.4% [178]. Thus, 
despite not commonly considered a complication of flu infection, skeletal muscle wasting during 
flu infection is more prevalent with aging [177] and leads to long term disability and loss of 
resilience. 
 
Central and peripheral nervous system complications 
There is a link between influenza and CNS manifestations. Neurologic complications from the 
flu include Reye’s syndrome, encephalopathy, encephalomyelitis, transverse myelitis, aseptic 
meningitis, focal neurologic disorders, and Guillain-Barre syndrome [179]. While these 
complications are rare, they occur more frequently in children and older adults [179, 180]. 
Additionally, it seems that immunogenetics play a role in neurological associated influenza 
complications.  
Influenza-associated encephalitis (IAE)/encephalopathy can be extremely severe and can affect 
all age groups, but the majority of patients were under 5 years of age and have 30% fatality rate 
[181, 182]. In a 21-person study of acute encephalopathy associated with flu infection, the ages 
spanned from 4-78 years with 5 patients >60 years, 8 patients 40-59 years, 2 patients 18-25 
years, 6 patients <12 years [183]. Impaired consciousness with IAE can put patients in a 
dreamlike state and leave them confused or faint. Acute necrotizing encephalopathy (ANE) has 
severe and sudden onset and is characterized by multiple brain lesions, frequently involving the 
thalami. In Japan there are about 10 cases of ANE per year, 28% are fatal and age-associated 
prevalence occurs in children under 5 years of age [181]. Other forms of encephalitis associated 
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with influenza include, acute encephalopathy with biphasic seizures (AESD), febrile seizures, 
and subcortical white matter lesions. Flu can trigger genetic predispositions for AESD in children 
<2 years old and has a low fatality rate, but high probability of recurring neurological issues 
including intellectual, motor deficits and epilepsy [181]. In less severe cases there is only mild 
encephalitis/encephalopathy with a reversible lesion (MERS) of the splenium of the corpus 
callosum, which is often associated with good clinical outcome. MERS usually resolves in about 
10 days and is most common type of encephalopathy among children aged 3-8 years [181]. 
Similar to MERS there is Posterior Reversible Encephalopathy Syndrome (PRES), where areas 
of edema via MRI are detected days to weeks after initial viral symptoms. In adult patient cases 
of PRES, the brain edema is often malignant, with elevated cytokines IL-8 and IL-10, but no 
detectable virus in the cerebral spinal fluid [184]. More severe conditions also arise from flu-
associated CNS disease such as acute hemorrhagic leukoencephalopathy (AHLE), which 
affects adults and children. Gonzalez et al observes a 46-year old mother and her 11-year old 
daughter both with AHLE [182]. AHLE is characterized by rapid and fulminant demyelination 
and inflammation of the white matter with possible links to flu-associated multiple sclerosis flair 
ups [181, 182].   
Flu-associated and multifaceted disease complications (observed in patients 4-78 years) do not 
occur in singlet, in fact, patients with IAE more frequently experience concurrent hepatic and 
renal function dysfunction, which could suggest a component of metabolic encephalopathy 
coexisting severe influenza illness rather than as a direct effect of virus itself [183]. 
Dysregulated immune responses have also been posited to drive neurologic complications in 
influenza. Serum levels of IL-6, TNF-α, and IL-10 were found to be significantly elevated in 
pediatric patients with IAE as compared to influenza-infected patients without neurologic 
involvement [185, 186]. Interestingly, elevated Il-6, TNF-α, and IL-10 has also been observed in 
the serum of older adults [187], suggesting that may also be at higher risk for these CNS 
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events. It is possible that CNS dysfunction in older adults may be over looked due to pre-
existing cognitive impairment, such as Alzheimer’s Disease or dementia, or may not associated 
with the flu infection itself due to confounding aging factors [187]. 
A correlative study on H3N2 flu virus-associated encephalopathy examined cytokine levels and 
NF-kB activation in peripheral blood mononuclear cells from 30 children with influenza virus-
associated encephalopathy at the acute stage of flu infection [185]. This study linked serum 
levels of IL-6, soluble tumor necrosis factor receptor-1 (sTNFR1), and IL-10 levels with flu virus-
associated encephalopathy. Higher NF-kB activation in peripheral blood mononuclear cells 
(PBMCs) in flu-associated encephalopathic patients’ groups was higher than patients with 
uncomplicated H3N2 influenza infection [185]. In young mice, A/Puerto Rico/8/1934 H1N1 flu 
virus induced neuroinflammatory responses paralleled loss of neurotrophic and glial regulatory 
factors in the hippocampus, and deficits in cognitive function. This suggests that flu-induced 
neuropathy that is observed clinically is likely due to neuroinflammation and can lead to 
cognitive declines [188]. Indeed, neuropathology with influenza is a real threat and it affects 
both mind and body resulting in observed loss of motor skills, reflexes, cognition, and more. 
Older adults are at greater risk for these complications due to many factors including elevated 
basal inflammation, pre-existing cognitive conditions, and other co-morbidities.  
 
Gastrointestinal and gut microbiota complications 
Flu infection can also be accompanied by gastrointestinal symptoms and other complications. 
Murine studies have supported these clinical associations as well. Flu infection itself induces gut 
microbiota dysbiosis through type I interferons (IFN-I) favoring proteobacteria overgrowth [189]. 
Such shifts can also impact T cell trafficking, differentiation, and even inflammatory responses. 
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In this instance there is a greater chance of secondary salmonella infection localized to the gut 
during or post flu infection [189].  
Common gastroenteritis-like symptoms in many flu infected patients include abdominal pain, 
nausea vomiting, and diarrhea [190-192]. In 6-10 week old male mice, lymphocytes derived 
from the respiratory mucosa migrated into the intestinal mucosa during flu lung infection via 
CCL25-CCR9 chemokine signaling, which destroyed the intestinal microbiota homeostasis in 
the small intestine and led to intestinal injury [193]. Respiratory influenza virus infection can also 
induce intestinal immune injury via microbiota-mediated Th17 cell-dependent inflammation 
[193]. Age-related changes, whether direct or indirect due to antibiotic treatment, may impair flu 
responses in older adults. In 8-16 week old CBA/J female mouse models, respiratory influenza 
virus infection induces intestinal immune injury via microbiota-mediated Th17 cell-dependent 
inflammation [117, 194]. 
Flu RNA has been found in stools of patients with confirmed flu infection and this ranged from 3 
to 71% in studies with children and 7.2% to 47% in studies on adults [192,195-202]. Altogether, 
the prevalence of flu virus in stool was 20.9% for patients in the above-mentioned studies [203]. 
Gastrointestinal symptoms, most commonly vomiting, were reported in 30.9% of the pandemic 
2009 H1N1 flu infections, 2.8% prevalent in seasonal H1N1 infection, 25.3% of influenza B virus 
infections and 21.9% for influenza A(H3N2) [203-205]. In theory, the already weakened immune 
system of older adults would be less prepared for these types of infections. 
 
Hepatic Complications 
Liver injury, from secondary systemic inflammation, mediated by viral infection is also an 
uncommon complication during flu infection, however this is observed in some older patients 
[120, 206]. Papic et al. examined pandemic 2009 flu patients (mean age of 46.79) compared to 
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seasonal flu patients (mean age of 47.06) and determined both illicit significant immune 
responses to infection leading to hepatocellular injury [206]. Additionally, Polakos et al. infected 
humans aged 18-45 years with 107 TCID50 influenza A/Kawasaki/86 (H1N1) virus to observe the 
flu-induced changes to the human liver [207]. Indeed, severe cases of flu have reported liver 
damage evident through elevated blood transaminases [alanine transaminase (AST) and 
aspartate transaminase (ALT)], bilirubin, and Gamma-glutamyl transferase (GGT) [206, 207]. 
Additionally, these elevations were associated with duration of hospitalization, hypoxia, and 
serum C-reactive protein (CRP) levels [206, 207]. Others have even noted centrizonal hepatic 
hemorrhagic necrosis in deceased pandemic flu patients ages 24-65 years upon autopsy [208, 
209], while Avian A(H5N1) and A(H7N9) were specifically connected with transaminase 
elevations [209, 210]. Beyond these threats, the liver is also susceptible to clots, hemorrhage, 
and less severely metabolic dysfunction [208, 209]. It is likely since there is increased systemic 
inflammation in older adults during flu infection, and that they may have pre-existing hepatic 
deficiencies, older adults may be more susceptible to hepatic complications during flu infection. 
In the context of future directions, more research should focus on the metabolic impact of flu 
infection on organs such as the liver, particularly in the context of aging. 
 
Renal Complications 
As with other complications, flu-associated renal complications are worse in those with pre-
existing risk factors, including obesity, chronic kidney disease, and increased age [211, 212]. 
Indeed, older adults are more likely to suffer from pre-existing renal impairment. Flu infection, 
even without severe complications such as rhabdomyolysis, can cause acute kidney injuries. 
Incidence of acute kidney injuries ranged from 18-66% in ICU admitted flu patients with the 
average age of 43 years and 13% of patients over 60 years [213-215]. Further, in the 2009 
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pandemic influenza A (H1N1) studies observed acute tubular necrosis (ATN), acute kidney 
injury was reported in up to 66% of critically ill adults (aged 25-50 years) and was associated 
with higher mortality rates [216-218]. These renal injuries are speculated to be due to decreased 
renal perfusion secondary to hypovolemia or a vasodilatory state of sepsis during severe flu 
infection. Importantly, renal function is regularly monitored in ICU admitted older adults for 
almost all infections. However, renal function and filtration declines with aging and the decrease 
of repair capacity leaves the organ vulnerable in older adults. In the context of future directions, 
there should be more research into the relation between kidney injury and flu infection so that 
more preventative action can be taken. 
 
Diminished immune responses with aging predispose older adults to common and 
uncommon influenza complications  
Diminished immune responses in older adults sets this population aside from others with pre-
existing vulnerability to influenza infection and its complications. In addition to weakened and 
delayed immune responses, older adults often struggle with recovery post infection due to 
extenuating complications. Indeed, the dysregulation of immune responses and increased 
systemic inflammation contribute to multiorgan complications that negatively impact older 
adults. The most common complication in older adults is secondary bacterial infection, such as 
bacterial pneumonia. Indeed, secondary bacterial infection is implicated in the majority of flu-
associated deaths in older adults. While commonly overlooked, uncommon complications, such 
as ARDS, often times follow pneumonia and can lead to advanced disease states. 
Extrapulmonary flu complications are also more common in older adults. The severity of flu-
associated myocarditis spans a wide spectrum ranging from asymptomatic to severe heart 
disease, though the relation to age is not clear. Interestingly, skeletal muscle more distal to the 
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site of infection also is affected by flu infection with older adults more at risk for weakness and 
muscle atrophy, often resulting in declines in physical function. Surprisingly, even separate from 
these instances of flu virus in the intestine, there are microbiota altering events during lung flu 
infection, which shift T cell population frequencies and induce dysbiosis. Adverse neurological 
and central nervous system complications with flu, mainly seen in pediatric and older adults, 
have associations with demyelination, encephalopathy, seizures, and cognitive declines. Other 
commonly overlooked complications from systemic inflammation and multiorgan disfunction 
include hepatic and renal systems which are already weakened in older adults from pre-existing 
complications. While vaccination reduces some of these common and uncommon 
complications, the negative impacts of flu infection are still evident in older adults. Thus, older 
adults need to be monitored more closely for flu-associated complications to prevent flu-
associated morbidities and disabilities.  
 
Skeletal muscle homeostasis 
Humans by age 80 have an estimated 30-40% less of skeletal muscle fibers when compared to 
young adults [219]. Skeletal muscle controls voluntary motion, but is also the body’s natural 
amino acid reservoir, in which amino acids are incorporated into myofibrillar proteins and 
cellular organelles with an average daily skeletal muscle protein turnover rate of 1-2% [220, 
221]. More importantly, to facilitate with wound healing, especially following traumatic 
injury/acute infection, the body requires a large and sustained supply of amino acids to heal 
properly [154, 155, 221]. The exact mechanism to sacrifice and degrade skeletal muscle for 
usable amino acid is unknown, but there have been several studies that have analyzed the 
egress of tagged amino acids from leg muscle to wound sites for repair/immune energy needs 
[220, 222, 223, 224, 225, 226, 227]. This process even occurs during fasting, which is an 
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inadvertent side-effect of influenza, thereby contributing to the demand for amino acid from 
skeletal muscle. On a clinical level, skeletal muscle injury can be observed by assessing serum 
creatine kinase levels, as well as serum myoglobin [154, 155, 221]. We hope to identify ways to 
reduce or stop this process to preserve skeletal muscle mass in aged individuals since their 
regenerative capabilities are weakened to the point where disability is guaranteed and there is 
no hope in completely regaining lost function/mass. 
 
Influenza vaccination 
The age-associated decline in immunity is partially the result of reduced production of high 
affinity neutralizing antibodies, which then increases susceptibility to pathogen invasion [228]. 
This is exacerbated by declines in T cell receptor repertoire diversity and the number of naïve T 
cells that are available to recognize a new pathogen. To improve upon these defects in the aged 
immune system, flu-vaccination is highly advised for older adults because of the added 
protection and improved efficacy/faster response [116, 229, 230]. Vaccination has the potential 
to prevent disability, irreparable damage, and even death in older adults. Nonneutralizing 
influenza vaccines have the capacity to protect the public against secondary bacterial diseases 
and reduce the pathogenicity of flu-infection when neutralizing vaccines are not available [230]. 
Chapter three of this thesis will evaluate vaccine-induced prior immunity and its effect on 
reducing flu-associated myopathy by comparing cellular immunity and humoral immunity. 
 
Goals of thesis 
The primary goal of this dissertation is to expand our understanding of how aging impacts 
various components of the immune response to influenza infection, with a focus on skeletal 
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muscle degradation and disability. Our hypothesis predicts that flu-induced systemic factors 
trigger skeletal muscle atrophy, which then impairs muscle function and its regenerative 
capacity in aged mice because of prolonged inflammation and inflammatory immune cell 
presence in the muscle. This research has laid the ground work for others to further 
characterize and test pathways/genes as mechanism(s) of flu-induced muscle degradation and 
dysfunction in aging. 
In chapter two, “Aging augments the impact of influenza respiratory tract infection on mobility 
impairments, muscle-localized inflammation, and muscle atrophy,” we elucidate how aging 
impacts several components of the flu response and myopathy. We determine the molecular 
link between pulmonary infection and skeletal myopathy. We also assess the contribution of the 
aged skeletal muscle function and environment in the promotion of impaired immune 
response/healing during influenza infection.  
In chapter three, “Vaccination mitigates influenza-induced muscular declines in aged mice,” our 
goal was to determine if prior immunity reduces flu-induced skeletal muscle decrements. We 
demonstrated that prior immunity, induced by vaccination, prevents muscle fast twitch fiber 
atrophy and consequently protects muscle functionality. This chapter is proof that despite 
decrease reduced vaccine efficacy with aging, there is still protection to muscle histology, 
function, and molecular signals.  
In chapter four, “Pathway Analysis of aged skeletal muscle RNA-Sequencing reveals strong 
leukocyte activity during pulmonary influenza infection,” the overarching scientific premise is 
based on our published study that demonstrated increased muscle atrophy during influenza 
infection with aging. We hypothesize that lingering systemic inflammation in aged individuals 
during flu infection and increased muscle sensitivity to this inflammation contributes to increased 
muscle-localized inflammation, cellular infiltration, and muscle atrophy. In our mouse model of 
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flu infection, we find functional decrements in skeletal, as well as molecular aberrations such as 
upregulation of muscle inflammatory and atrophy gene expression and down regulation of 
positive muscle regulators. Our goal in this project is to identify mediators involved with age-
related flu-induced myopathies that will help us to formulate mechanistic hypotheses about how 
this happens and how it can be prevented in order to keep older adults healthier longer. 
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Aging augments the impact of influenza respiratory tract infection on 
mobility impairments, muscle-localized inflammation, and muscle atrophy 
 
ABSTRACT 
Although the influenza virus only infects the respiratory system, myalgias are commonly 
experienced during infection. In addition to a greater risk of hospitalization and death, older 
adults are more likely to develop disability following influenza infection; however, this 
relationship is understudied. We hypothesized that upon challenge with influenza infection, 
aging would be associated with functional impairments together with upregulation of skeletal 
muscle inflammatory and atrophy genes. Infected young and aged mice demonstrated 
decreased mobility and altered gait kinetics. These declines were more prominent in hind limbs 
and in aged mice. Skeletal muscle expression of genes involved in inflammation, as well as 
muscle atrophy and proteolysis, increased with influenza with an elevated and prolonged peak 
in aged mice. Infection also decreased expression of positive regulators of muscle mass and 
myogenesis components to a greater degree in aged mice. Gene expression correlated to 
percent body mass loss, although evidence did not support direct infection of muscle. Overall, 
influenza leads to mobility impairments with induction of inflammatory and muscle degradation 
genes and downregulation of positive regulators of muscle. These effects are augmented and 
prolonged with aging, providing a molecular link between influenza infection, decreased 





It is well established that immune function declines with aging. Immunosenescence of both the 
innate and adaptive immune systems result in increased susceptibility to infection, as well as 
increased severity of infection in older adults. Influenza (flu) tends to be particularly problematic 
in older adults with increased risk for serious complications and hospitalization. Approximately 
90% of flu-related deaths occur in older adults [1], with influenza and pneumonia being the 
seventh leading cause of death among persons over 65 years old in the United States [2]. Even 
when death is avoided, older adults have increased risk of morbidity and disability from flu 
infection. Flu-related hospitalizations are associated with increased loss of independence [3] 
and long term declines in activities of daily living are observed post flu infection among nursing 
home residents [4]. Further, flu is among the leading causes of catastrophic disability and 
dramatic losses of activities of daily living in older adults [5]. While it is known that prolonged 
hospitalization of older adults is associated with decreased muscle mass and strength; flu 
infections, independent of hospitalization, have some degree of muscle involvement with 
myalgia among the common symptoms even in uncomplicated infections [6].  
While myalgia is a common non-pulmonary symptom of flu infection, other myopathies are less 
commonly reported. Interestingly, despite increased clinical severity in older adults, most flu 
associated myopathies are reported in pediatrics [7, 8], though it is possible, and quite likely, 
that older adult myopathies are under reported and not the primary focus of care due to other 
more life-threatening complications. In pediatric populations the most common flu-associated 
myopathy is acute myositis, characterized by severe calf pain, difficulty walking, and altered gait 
that generally resolves on its own within 30 days, but more commonly within a week [7, 8]. Less 
frequently acute myositis has also been reported in both adults [9] and older adults [10]. In a 
range of ages, elevated circulating markers of muscle damage, such as creatine kinase (CK), 
myoglobin, and lactate dehydrogenase, have been reported during flu infection [7-13]. 
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Additionally, during flu pandemics there have been cases of rhabdomyolysis reported [14-16] 
and muscle biopsies have confirmed atrophic/necrotic muscle fibers, though inflammatory cell 
infiltration seems less common [7, 17]. Furthermore, during the 2009 H1N1 flu pandemic, 
elevated serum CK was associated with worse flu outcomes (length of intensive care unit stay, 
increased pulmonary, kidney, and other non-pulmonary complications) [11].  
Nevertheless, the flu virus demonstrates great specificity for pulmonary epithelial cells, with all 
evidence indicating that in all or nearly all cases active infection remains limited to the 
respiratory system [6]. Thus, while a wealth of literature indicates symptomatic or functional 
muscle involvement with pulmonary flu infection, it is unclear if these complications only occur in 
severe infections or if they are under reported and under studied in less severe infections. The 
limited research regarding flu-induced myopathy pathogenesis is controversial; direct viral 
infection of the muscle and immune-mediated cytokine storm induced muscle damage are 
among the top hypotheses. While some in vitro studies have shown that myoblasts and 
myotubes may be susceptible to infection and might produce live viral progeny [18-20], isolation 
of virus from muscle biopsies is rare [12, 21-23]. In vivo murine experiments showed that a non-
permissive infection is possible in mature muscle fibers, though this is more likely with 
intramuscular inoculation [24-26], so the clinical relevance of these experiments remains entirely 
unclear.  
While the pathogenesis of flu-associated myalgia and myopathy has yet to be determined, their 
clinical significance is apparent. Though flu-induced myopathies in pediatric cases are not long 
lasting conditions with permanent effects, it is possible that due to decreased resilience in older 
adults flu-induced myopathies may be prolonged and have lasting effects; leading to the 
increased disability and loss of independence observed post flu [3-5, 27]. As the aging 
population continues to grow, emphasis on extending healthspan and increasing resilience is 
necessary [28]. Flu and possibly other respiratory tract infections may represent an under 
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reported risk factor predisposing older adults to sarcopenia, frailty, and overall decreased 
resilience. Here, in a well-validated murine model of flu infection, we aimed to characterize flu 
effects on skeletal muscle, both from a functional and molecular perspective, in both young and 
aged mice. We hypothesized that during flu infection aging would be associated with diminished 
mobility and functional performance together with upregulation of skeletal muscle inflammatory 




Young (2.5-4 month old) C57BL/6 male mice were obtained from Charles River Laboratories 
and aged (19-22 month old) C57BL/6 male mice were obtained through the National Institute on 
Aging rodent colony. All mice were housed in a climate controlled environment with 12:12 
light:dark cycle and fed standard rodent chow and water ad libitum. All procedures were 
approved by the University of Connecticut Medical School IACUC (protocol 100705) and carried 
out in accordance with these regulations. All mice underwent gross pathological examination at 
time of sacrifice and animals with obvious pathology were excluded from the study.  
 
Viral Infection  
Mice were anesthetized with isoflurane and intranasally inoculated with 50μl of 500 EID50 of 
influenza virus A/PR/8/34 (PR8). Mice were weighed daily to monitor infection progression. At 
time points indicated, whole lung tissue was homogenized and RNA was isolated via RNeasy 
Mini Kit (Qiagen Inc., Valencia, CA). RNA was reverse transcribed with iScript cDNA synthesis 
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Kit (Bio-Rad Laboratories, Inc., Hercules, CA) and flu viral copies were detected via reverse 
transcription quantitative PCR of flu acid polymerase (PA).  
 
Voluntary Locomotor Activity 
Spontaneous voluntary locomotor activity was measured via open field test at time points 
indicated. All tests were performed between 6-8am to control for diurnal variations. Following 
acclimation to the dim-lit testing room (at least 1 hour), mice were placed in the center of the 
photobeam activity system-open field (PAS-OF, 16”x16”x15” acrylic animal enclosure, San 
Diego Instruments, San Diego, CA) and their activity was recorded for 20 minutes. The first 5 
minutes was excluded as this is generally considered to be exploratory behavior rather than 
general voluntary locomotor activity. The number of beam breaks per minute during the last 15 
minutes was then used to assess voluntary locomotor activity.  
  
Gait Analysis 
Gait analysis was performed using the DigiGait instrument (Mouse Specifics, Inc, Quincy, MA) 
and software (DigiGait Imager 4.0.0 and DigiGait Analysis 11.5, Mouse Specifics, Inc). The 
DigiGait instrument consists of a clear treadmill with a high-speed camera mounted underneath 
that collects images at 147 frames per second for high resolution of postural temporal gait 
parameters. Mice run within a 2” wide acrylic running chamber at set speeds. The ventral plane 
videos are analyzed with the DigiGait software which identifies portions of the paw that are in 
contact with the treadmill belt to produce both postural and kinematic gait parameters. Mice 
were introduced to the DigiGait system at a low speed (10cm/sec) briefly (30 seconds) prior to 
the initial testing. Mice were allowed to acclimate to the dim-lit room for 1 hour prior to each 
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testing period and all tests were performed between 6-8am. Mice ran at the testing speed 
(16cm/sec) until approximately 5 seconds of consecutive walking was recorded and this video 
segment was analyzed via DigiGait software.  
 
Gastrocnemius Reverse-Transcription Quantitative PCR (RT-qPCR) 
At the time points indicated for gastrocnemius gene expression mice were fasted with the 
exception of water for 4-6 hours prior to sacrifice to minimize potential confounding results due 
to postprandial muscle protein synthesis. The gastrocnemius muscle was dissected and placed 
in RNAlater (Qiagen Inc.) overnight at 4⁰C. RNAlater was removed and gastrocnemius was 
frozen at 80⁰C until RNA extraction. The muscle was homogenized and RNA was extracted via 
RNeasy Fibrous Tissue Mini Kit (Qiagen Inc.). RNA quantity and quality were assessed with 
Nanodrop 2000c (Thermo Scientific, Waltham, MA) and was reverse transcribed via iScript 
Advanced cDNA synthesis Kit (Bio-Rad Laboratories, Inc.). RT-qPCR was performed using 
custom designed PCR plates with predesigned commercially available primers (Bio-Rad 
Laboratories, Inc.). Gene expression was calculated via a modified Pflaffl method utilizing 
multiple reference genes (RPS18 and TBP, which showed the least variability between 
conditions and thus suitable reference genes) and normalized to gene expression of young mice 
at Day 0 prior to infection to give comparable fold changes. 
 
In Vitro Myoblast Culture and Infection 
Harvested leg skeletal muscle (gastroc, vastus medialis, vastus lateralis, soleus, anterior tibialis) 
from uninfected young and aged mice was incubated in collagenase type IIA and dissociated in 
growth media (Dulbecco modified Eagle’s medium (D-MEM) supplemented with 20% fetal 
52 
 
bovine serum (FBS), 1% penicillin/streptomycin, 5ng/mL basic fibroblast growth factor (bFGF)) 
and grown on extracellular matrix-coated plates (extracellular matrix, Sigma-Aldrich Corp., St. 
Louis, MO). When myoblasts reached ~50% confluency, they were purified via plating on an 
uncoated Petri dish to remove any adherent fibroblasts. Myoblasts were then seeded at 150,000 
cells per well in coated 6-well plates and allowed to grow to 50% confluency prior to infection. 
For infections, myoblasts were washed twice with phosphate buffered saline (PBS) and 
incubated for one hour with 0, 10, or 100 EID50 PR8 in D-MEM supplemented with 1% 
penicillin/streptomycin. Then myoblasts were washed twice with PBS and cultured with growth 
media for the remaining days. Culture media at time points indicated was analyzed for 
cytokine/chemokine concentrations via multiplex (25Plex Magnetic Bead Panel, EMD Millipore, 
Billerica, MA). Most cytokine/chemokines were below detectable limits (GCSF, GMCSF, IFN-γ, 
IL10, IL12p40, IL12p70, IL13, IL15, IL17, IL1β, IL1α, IL2, IL4, IL5, IL7, IL9, MIP1β, MIP1α, 
MIP2, RANTES, TNF-α). Total RNA was extracted via TRIzol (Ambion, Life Technologies, 
Grand Island, NY) according to manufacturer’s recommendation. RNA was reverse transcribed 
and flu viral copies were detected via real-time quantitative PCR of flu PA. 
 
Statistical Analysis 
Weight loss, viral titers, functional performance, and log-transformed gastroc gene expression 
results were analyzed via 2-way ANOVA (age x time point) with Bonferroni posthoc corrections 
when indicated with significance set a p<0.05. Genes were considered differentially expressed if 
fold changes were > 2 and p<0.05. In vitro myoblast supernatant and RNA were analyzed via 3-
way ANOVA (age x infection condition x time point) and 2-way ANOVA (age x infection 
condition), respectively, with Bonferroni posthoc corrections when indicated with significance set 
at p0.05. Univariate linear regression was used to compare the relationship between gastroc 
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gene expression and percentage weight loss independently for each variable that showed time 
effects with significance set at p<0.05. Step-wise multiple regression analysis was used to 
determine if multiple variables could better predict percent weight loss.  
 
RESULTS 
Following influenza infection aged mice have prolonged weight loss and elevated lung viral titers 
Young and aged mice were infected intranasally with a sublethal dose (500 EID50) of influenza 
A/PR/8/34 (PR8). Percent weight loss following infection is more severe and prolonged in aged 
mice (Fig 1A). While young mice begin to gain body mass by 10 days post infection (DPI), aged 
mice do not recover as quickly and differences between young and aged mice exist on 10-15 
DPI. In the aged groups, increased weight loss is accompanied by slower viral clearance (Fig 
1B) as measured by influenza polymerase (PA) copies in whole lung tissue via RT-qPCR. 
Although weight loss is a common marker used for pathogenicity in mice, it is rarely considered 
as a relevant outcome measure and mechanisms involved remain unknown. 
 
Figure 1. Prolonged weight loss and elevated flu titers in aged mice during flu infection. Young and 
aged C57BL/6 mice were intranasally infected with 500 EID50 of PR8 influenza. (A) Weight loss was 
monitored throughout the infection and percent weight loss was calculated from day 0 prior to infection. 
Data shown as mean ± SEM. Two-way ANOVA with Bonferroni posthoc corrections showed significant 
weight loss (compared to day 0) on day 6 through 15 (not indicated in figure) and differences between 
young and aged mice at time points indicated (* = p<0.05). (B) On day 0, 3, 7, 11, and 15 whole lung 
tissue was harvested and RNA was isolated. Total number of copies of influenza PA was determined via 
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RT-qPCR. Data shown from one independent experiment with individual samples as dots, mean and 
SEM indicated by line and error bars, respectively. Two-way ANOVA with Bonferroni posthoc corrections 
showed significant viral burden following flu infection (compared to day 0, p<0.05, indicated by brackets 
above data) and differences between young and aged mice at time points indicated (* = p<0.05). 
Influenza infection induces impairments in voluntary locomotor activity and gait parameters in 
young and aged mice 
To assess functional decrements associated with flu infection, we examined both voluntary 
activity levels, as well as more sensitive postural and kinematic gait alterations. Decreased 
voluntary locomotor activity was evident by 3 DPI in both young and aged mice as assessed by 
beam breaks in the open field test (Fig 2A). Diminished activity persisted through 20 DPI. Aged 
mice had fewer beam breaks per minute than their young counterparts on 11 (77.9% fewer), 15 
(67.5% fewer), and 20 DPI (63.1% fewer) indicating that flu-induced decreased voluntary 
locomotor activity is more pronounced and prolonged in aged mice. 
More detailed analysis of walking patterns was performed using the DigiGait system, which 
employs ventral plane videography to assess both spatial and temporal indices of gait at a given 
speed. Preliminary studies determined that 16cm/s was a speed that both young and aged mice 
could complete without difficulty and have consistent gait patterns for analysis (data not shown). 
Throughout the course of flu infection, no significant changes in stride, swing, or stance duration 
were observed (data not shown); however, alterations in postural components and acceleration 
parameters existed. By 7 DPI mice reduced stance width of both the fore (Fig 2B) and hind (Fig 
2E) limbs by 15% and 13%, respectively, compared to baseline. Interestingly, aged mice initially 
had a wider fore limb stance, but these differences were concealed later in the infection. More 
pronounced differences in flu-induced gait alterations between the young and aged mice were 
observed in the midline distance of the fore (Fig 2C) and hind limbs (Fig 2F) later in infection, 
with hind limb midline distance being 46% narrower in aged mice compared to young mice on 
20 DPI. This indicates aged mice are reaching less from their center with every step, perhaps 
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due to increased muscle and joint pain limiting mobility. Additionally, later in the infection aged 
mice have increased stride length variability in the hind limbs compared to the young mice (Fig 
2J). Gait symmetry index of the fore/hind limbs (Fig 2D) was increased in both young and aged 
mice at 11 DPI and 15 DPI as well, indicating a greater number of steps were taken with the 
fore limbs compared to the hind limbs.   
Acceleration and deceleration measures were also affected by flu infection. The maximal rate of 
change of paw area contact during the braking phase (Max dA/dt), or how rapidly the mouse 
decelerates, is decreased in the fore (Fig 2H) and hind limbs (Fig 2K) later in the infection, 
though more pronounced in the hind limbs. Similarly, the maximal rate of change in paw area 
contact during the propulsion phase (Min dA/dt), or how rapidly the mouse propels itself into the 
next step, is decreased in the hind limbs by 7 DPI, but recovered by 20 DPI (Fig 2L). Both 
acceleration and deceleration are important parameters indicating the rate of force 
development, an important component of muscle health and quality. Interestingly, decreased 
Max dA/dt was still evident at 20 DPI. 
Taken together, alterations in gait include decreased force development accompanied by 
decreased reaching distance and a narrower stance, more marked in the hind limbs and in aged 
mice. Diminished voluntary locomotor activity is prolonged in the aged mice as well. Functional 
impairments may be indicative of flu-induced muscle inflammation and damage, and that this is 




Figure 2. Influenza infections induces functional decrements in both voluntary locomotor activity 
and gait kinematics that is more pronounced in the hind limbs and in the aged mice. Young and 
aged C57BL/6 mice were intranasally infected with 500 EID50 of PR8 influenza. On days 0, 3, 7, 11, 15, 
and 20 mice were tested for functional performance. (A) Spontaneous voluntary activity was assessed via 
the open field test on a photobeam activity system. Beam breaks were recorded as mice traveled at 
16”x16” open field and locomotor activity was assessed as beam breaks per minute. Gait parameters 
were assessed utilizing DigiGait, a ventral plane videography treadmill system. Postural gait parameters 
(Stance width of the fore (B) and hind (E) limbs and midline distance of the fore (C) and hind (F) limbs) 
were altered during flu infection with more prominent results in the hind limbs of aged mice. Kinematic 
gait parameters were also altered with flu infection. Gait symmetry of the fore/hind limbs (D) was 
increased. Stride length variability of the fore limb (G) did not change, however the aged mice had 
increased stride length variability in the hind limbs later in the infection (J). Maximal rate of change of paw 
area contact during the breaking phase (Max dA/dt) and propulsion phase (Min dA/dt) is altered in the 
fore (H and I, respectively) and hind limbs (K and L, respectively) with more dramatic results in the hind 
limbs. All data analyzed via two-way ANOVA with Bonferroni posthoc corrections with effect of flu 
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infection over time (compared to day 0, p<0.05) indicated by brackets above data and differences 
between young and aged mice (p<0.05) at time points indicated by asterisk. 
Influenza induces altered inflammatory gene expression in skeletal muscle  
Since alterations in gait were primarily in hind limbs, the gastrocnemius (gastroc) muscle gene 
expression was further examined over the course of flu infection in young and aged mice. As 
hypothesized, inflammatory gene expression in the gastroc was altered over the course of the 
flu infection. By 7 DPI flu induced increased gene expression of interleukin (IL)-6 (IL6) and IL-6 
receptor alpha (IL6RA) (Fig 3A and Fig 3B). IL6RA expression remained elevated by 3.6 fold in 
the aged mice at 11 DPI while the young mice returned to baseline expression levels. Aged 
gastroc had 2.7-fold increased expression of tumor necrosis factor (TNF) at baseline and these 
differences were intensified on 15 DPI with 6.7-fold greater expression of TNF in aged gastroc 
(Fig 2C). IL-6 and TNF are two key inflammatory mediators in skeletal muscle degeneration and 
repair, signaling through STAT3 and NFB, respectively, that have vast effects on pro-
inflammatory signaling, protein degradation, and atrophy gene induction (reviewed in [29]). 
Additionally, a dramatic 43-fold increase in expression of chemokine (C-X-C Motif) Ligand 10 
(CXCL10), a predominant player in T helper (Th) 1 responses that recruits immune cells, 
particularly T lymphocytes expressing its receptor CXCR3, into tissue, was observed in the 
aged gastroc at 11 DPI (Fig 3D). Prolonged and exaggerated levels of CXCL10 would increase 
immune cell recruitment and muscle inflammation, and potentially impair muscle regeneration 
processes.  
Taking these results collectively, flu induced lingering inflammation in the aged muscle. As it is 
known that these inflammatory mediators signal through NFB and other pathways that induce 





Figure 3. Influenza infection induces muscle-localized inflammatory gene expression in the 
gastrocnemius that is prolonged and elevated in aged mice. Young and aged C57BL/6 mice were 
intranasally infected with 500 EID50 of PR8 influenza. At day 0, 3, 7, 11, and 15, mice were fasted for 4-6 
hours prior to sacrifice and gastrocnemius muscle was harvested and RNA was isolated. Gene 
expression was analyzed via RT-qPCR and normalized to reference genes and expression of young mice 
at day 0 to indicate fold changes. Influenza induced increased expression of IL6 (A) and IL6RA (B). 
Increased TNF (C) and CXCL10 (D) expression was observed in the aged mice. All data was log-
transformed and analyzed via two-way ANOVA with Bonferroni posthoc corrections with effect of flu 
infection over time (compared to day 0, p<0.05) indicated by brackets above data and differences 
between young and aged mice (p<0.05) at time points indicated by asterisk. 
Increased expression of protein degradation and muscle atrophy genes post influenza infection 
is prolonged in aged mice 
Although there are many pathways involved in protein degradation and atrophy, we focused on 
the ubiquitin proteasome pathway, primarily the muscle-specific E3 ubiquitin ligases atrogin-1 
(also known as muscle atrophy F-box (MAFbx)) and muscle RING finger 1 (MuRF1), as the 
majority of literature to date shows increased atrogin-1 and/or MuRF1 expression at some point 
during almost all conditions of muscle wasting and atrophy [30]. As part of the ubiquitin 
proteasome pathway, atrogin-1 and MuRF1 control the ubiquitination and therefore degradation 
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of specific target proteins in response to key signals. Key initiators of these pathways include 
inflammatory cytokines, as well as myostatin, glucocorticoids, FoxO transcription factors, and 
others. Following flu infection, we observed increased gastroc gene expression of both 
myostatin (MSTN) and FOXO1 at 7 DPI (Fig 4C and 4D), by 2.0- and 2.3-fold change, 
respectively. FOXO1 remained elevated at 11 DPI, while MSTN elevation was only transient. 
Interestingly, FOXO1 was elevated in the young compared to aged mice at baseline and 3 DPI.  
Corresponding with elevated cytokines, myostatin, and FOXO1 expression, both ATROGIN1 
and MuRF1 gene expression were elevated with flu infection at 7 DPI by 2.1 and 5.3-fold, 
respectively. Moreover, in accordance with the prolonged inflammation, aged mice ATROGIN1 
and MuRF1 expression remained elevated at 11 DPI (Fig 4A and Fig 4B). While in young mice 
ATROGIN1 and MuRF1 expression was already decreased to below baseline levels (-2.6 and -
2.3-fold, respectively) at this time point, in aged mice expression remained elevated 2.3 and 2.5-
fold, respectively. Interestingly, ATROGIN1 was downregulated by 15 DPI, perhaps indicating 
an attempt to limit muscle degradation and begin repair processes. Baseline expression of 
MuRF1 was decreased in aged mice, while no significant baseline differences existed in 
ATROGIN1 expression. The influence of atrogin-1 and MuRF1 mRNA and protein expression 
on solely age-related muscle loss has yet to be resolved; some murine studies agree with our 
findings and show baseline suppression [31], while others have shown increased expression 
[32], and human studies have shown no differences [33, 34]. Nonetheless, induction of atrogin-1 
and MuRF1 in response to flu infection indicates increased ubiquitination and proteolysis within 
the muscle. Furthermore, expression of two ubiquitin proteasome encoding genes, ubiquitin B 
(UBB) and ubiquitin C (UBC), was also increased with flu infection with a 2.6- and 3.6-fold 
increase at 7 DPI (Fig 4E and Fig 4F). These increases were more dramatic and prolonged in 
aged mice. In young mice UBC expression peaked at 7 DPI, while aged mice continued 
increasing expression to a staggering 9.8-fold increase at 11 DPI.  The increased levels of UBB 
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and UBC, as well as ATROGIN1 and MuRF-1 indicate a catabolic environment of increased 
proteolysis, promoting muscle atrophy. 
 
Figure 4. Influenza infection induced gastrocnemius expression of components of the ubiquitin 
proteasome pathway that is more dramatic in aged mice. Young and aged C57BL/6 mice were 
intranasally infected with 500 EID50 of PR8 influenza. At day 0, 3, 7, 11, and 15, mice were fasted for 4-6 
hours prior to sacrifice and gastrocnemius muscle was harvested and RNA was isolated. Gene 
expression was analyzed via RT-qPCR and normalized to reference genes and expression of young mice 
at day 0 to indicate fold changes. Influenza induced increased skeletal muscle expression of negative 
muscle regulators (Myostatin (MSTN, C) and Forkhead box protein O1 (FOXO1, D)), as well as ubiquitin 
proteasome components (Atrogin1 (A), MuRF1 (B), Ubiquitin B (UBB, E), and Ubiquitin C (UBC, F)). All 
data was log-transformed and analyzed via two-way ANOVA with Bonferroni posthoc corrections with 
effect of flu infection over time (compared to day 0, p<0.05) indicated by brackets above data and 
differences between young and aged mice (p<0.05) at time points indicated by asterisk. 
Influenza infection decreases expression of positive regulators of muscle growth 
Increased atrogin1/MuRF-1 pathway components, as well as increased inflammatory cytokines, 
are associated with diminished muscle growth; however, following injury or atrophy muscle 
generally has a remarkable capacity to regenerate and repair. Muscle regeneration through 
myogenesis is regulated at many key steps by myogenic regulatory factors (MRFs), myocyte 
enhancer binding factors 2 (Mef2), and other growth factors. Thus, we next examined the gene 
expression of positive regulators of muscle growth following flu infection to determine if repair 
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processes are suppressed during this time and/or if muscle regeneration follows after atrophic 
responses with flu. At 7 DPI when atrophy and ubiquitin genes are upregulated, gastroc IGF1 
expression is reduced in both young and aged mice (Fig 5A). This was transient in the young 
mice, but remained downregulated in the aged mice through 11 DPI. During flu infection gastroc 
PAX7, a marker of satellite cells which are critical for adding myonuclei and regenerating 
muscle tissue, expression is decreased at 7 DPI in both young and aged mice, but to a greater 
degree in aged mice, less than one-fold reduction compared to ~3.5-fold reduction in the aged 
(Fig 5D). Similarly, at this time the expression of both MYOD1 and MYOG, key MRFs, was 
decreased to a greater degree, with approximately 7- and 2-fold reductions, respectively, in the 
aged mice (Fig 5E and 5F). MEF2C, which acts in concert with the MRFs to control DNA 
binding and transcriptional regulation, was also suppressed at this time point and remained 
suppressed at 11 DPI in the aged mice (Fig 5B).  
In summary, flu suppressed positive regulators of muscle mass and regeneration with 
concurrent increases in negative regulators. Additionally, these responses were greater and/or 




Figure 5. Influenza infection reduced gastrocnemius expression of positive regulators of muscle 
mass and myogenic regulatory factors to a greater degree in aged mice. Young and aged C57BL/6 
mice were intranasally infected with 500 EID50 of PR8 influenza. At day 0, 3, 7, 11, and 15, mice were 
fasted for 4-6 hours prior to sacrifice and gastrocnemius muscle was harvested and RNA was isolated. 
Gene expression was analyzed via RT-qPCR and normalized to reference genes and expression of 
young mice at day 0 to indicate fold changes. Influenza reduced skeletal muscle expression of insulin-like 
growth factor 1 (IGF1, A), myocyte enhancer binding factor 2C (MEF2C, B), paired box protein 7 (PAX7, 
C), myogenic differentiation 1 (MYOD1, D), and myogenin (MYOG, E). All data was log-transformed and 
analyzed via two-way ANOVA with Bonferroni posthoc corrections with effect of flu infection over time 
(compared to day 0, p<0.05) indicated by brackets above data and differences between young and aged 
mice (p<0.05) at time points indicated by asterisk. 
Flu induced weight loss is correlated with gastroc gene expression of ubiquitin proteasome 
components 
In order to determine if flu-induced weight loss was associated with muscle degradation, we 
performed correlation analysis on all variables that exhibited a time effect over the course of the 
flu infection. Indeed, multiple variables had significant correlations and age interactions were 
evident (Fig 6). In both young and aged mice FOXO1 (Fig 6A), IL6RA (Fig 6B), UBB (Fig 6C), 
UBC (Fig 6D), and MuRF1 (Fig 6E) were significantly correlated with percent body mass where 
UBC accounted for the greatest variation with R2 = 0.487 and 0.541 in young and aged mice, 
respectively (Fig 6D). Interestingly, a significant correlation was observed with IGF1 expression 
in young mice that was not evident in aged mice (Fig 6G), and the opposite was observed with 
ATROGIN1 expression (Fig 6F).  
Further, all variables that had any significant correlations per age group were placed in a step-
wise multiple regression analysis to determine if multiple variables could account for greater 
variability. In young mice UBC, IGF1, and MuRF1 expression accounted for approximately 71% 
of variability seen in body mass changes (adjusted R2= 0.714, p=0.007), with additional 
variables not adding significantly to the model. In contrast, in aged mice UBC expression 
accounted for approximately 58% of the variability in body mass (adjusted R2= 0.576, p<0.001) 
with no other variables tested (ATROGIN1, MuRF1, IL6RA, UBB, and FOXO1) adding 




Figure 6. Influenza induced weight loss is correlated with gastrocnemius gene expression of 
ubiquitin proteasome pathway components. Percent weight loss at time of sacrifice and corresponding 
gastrocnemius gene expression was analyzed via univariate linear regression for all genes that showed 
significant time effects. Young and aged mice were analyzed separately to determine if relationships vary 
with age. FOXO1 (A), IL6RA (B), UBB (C), UBC (D), MURF1 (E), ATROGIN1 (F), and IGF1 (G) were 
significantly correlated with percent body mass in either young or aged, or both (Young (Y) and aged (A) 
mice regression analysis p and R2 values indicated to right of graph, bolded if significant (p<0.05)), while 
no relationship was seen with percent body mass and expression of IL6, TNF, CXCL10, MEF2C, PAX7, 
MYOD1, and MYOG (data not shown). 
Negligible viral copies detected in the gastrocnemius post influenza infection in vivo 
Since flu-induced weight loss was correlated with gastroc gene expression, we next examined a 
potential mechanism; direct infection of the skeletal muscle in vivo. RNA harvested from the 
gastroc was probed for the flu PA similar to as performed on whole lung tissue. Though rare 
case studies have identified virus particles in muscle biopsies of influenza infected humans with 
myalgia, this highly unusual finding may be limited to critically ill and preterminal cases [12, 21-
23]. Indeed, flu PA was not detectable in the majority of gastroc tissue and the few samples that 
had detectable levels of flu PA had only negligible levels (Fig 7A). Since there was an 
upregulation of muscle degradation genes in all mice by day 7 post infection, the mechanism of 




Figure 7. The pathogenesis of influenza-induced myopathies is likely not direct infection of 
skeletal muscle as viral copies are not seen in the gastrocnemius muscle. Young and aged 
C57BL/6 mice were intranasally infected with 500 EID50 of PR8 influenza. (A) On day 0, 3, 7, 11, and 15 
whole gastrocnemius was harvested and RNA was isolated. Total number of copies of influenza PA was 
determined via RT-qPCR with a positive control used (infected mice lung tissue). Uninfected young and 
aged murine myoblasts were incubated with 0, 10, or 100 EID50 PR8 influenza for one hour and then 
were cultured in growth media. Myoblast supernatant was analyzed for chemokine/cytokines via multiplex 
assay. Detectable cytokines were analyzed by 3-way ANOVA (age x infection condition x time point). 
While a significant age effect was observed (p<0.05), there was no effect of infection and no interaction of 
infection and time for myoblast secretion of IL6 (C), CXCL10 (D), CXCL1 (E), and CCL2 (F). At 96 hr post 
infection, total RNA from the myoblast culture was extracted and total number of copies of influenza PA 
was determined via RT-qPCR. No viral copies were present in in vitro myoblast cultures (B). 
In vitro myoblasts do not harbor active influenza infection 
To further investigate the possibility that direct infection of skeletal muscle could occur, we 
harvested leg skeletal muscle (gastroc, vastus medialis, vastus lateralis, soleus, and anterior 
tibialis) of uninfected young and aged mice. Myoblasts were harvested, grown, purified, and re-
plated prior to infection. Myoblasts were incubated for 1 hour with 0 EID50, 10 EID50, or 100 
EID50 PR8. Supernatants were collected at 24, 48, and 72 hours post infection and 
cytokine/chemokine concentration were determined via multiplex (Fig 7C, 7D, 7E, and 7F). IL-6 
secretion was significantly greater from the aged myoblasts, (age effect: p<0.001), but was not 
affected by infection or infection over time (infection effect: p=0.600, infection*time interaction 
effect: p=0.583, Fig 7C). The same pattern was observed for CXCL10 (age: p<0.001, infection: 
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p=0.609, infection*time: p =0.684, Fig 7D), CXCL1 (age: p<0.001, infection: p=0.865, 
infection*time: p =0.121, Fig 7E), and CCL2 (age: p<0.001, infection: p=0.921, infection*time: p 
=0.263, Fig 7F). Thus, cytokine secretion was affected by age, but not by flu infection. 
Myoblasts were harvested and RNA was extracted at 96 hours post infection to probe for flu PA 
copies as previously done. Though some studies [18-20], show that myoblasts can be infected 
by influenza in vitro, our results indicate that both young and aged myoblasts are not 
susceptible to a productive flu infection (Fig 7B). 
DISCUSSION 
Studies addressing the pathophysiology of flu infection typically focus on respiratory and 
immune systems, while those seeking to understand aging-related declines in mobility 
performance emphasize muscle biology and relevant neural systems. Nevertheless, it has 
become clear that systems-based approaches are essential to both aging research and clinical 
care of older adults since a failure to think more broadly fails to consider crosscutting biological 
themes and motifs in aging and also ignores crucial bidirectional signals between different 
systems and tissues. With these considerations in mind, we have investigated the potential 
clinical significance of flu-associated myalgia and myopathies in relation to flu-induced disability 
in older adults. Indeed, we have shown that flu infection induces both functional decrements and 
upregulation of muscle inflammation and atrophy gene expression that is more pronounced with 
aging, indicating the impact of flu infection on muscle may directly predispose older adults for 
catastrophic disability and sarcopenia. Additionally, the functional alterations observed during flu 
infection may increase risk of falls and other musculoskeletal injuries. Thus, here we have 
identified flu infection as a previously unrecognized, but potentially targetable, inducer of muscle 
atrophy potentially leading to decreased resilience in older adults.  
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Aged mice have more severe and prolonged weight loss, as well as increased lung viral titers 
and delayed viral clearance following sublethal flu infection [35]. Similarly, voluntary locomotor 
activity is decreased with flu infection, and this reduction is prolonged in aged mice. However, 
since it is possible that voluntary activity could be diminished due to general flu-induced 
malaise, we analyzed gait patterns to assess more specific flu-induced alterations in functional 
performance. We showed that aged mice initially had a wider fore limb stance compared to 
young mice, but this was decreased with flu. It is known that older adults generally increase 
stance width to increased stability [36, 37], though this relationship is not yet established in 
mice. Midline distance was also decreased with flu infection and this was more dramatic in the 
hind limbs of the aged mice. Narrower steps with flu infection likely lead to decreased balance, 
potentially leading to increased risk for injury, as narrower stride width is associated with 
increased fall risk in older adult humans [36]. Stride length variability and gait symmetry index 
also increased with flu infection and is more prominent in the aged mice. Indeed, gait variability 
is also a predisposing factor for falls in older adults [38, 39]. Additionally, we showed 
decrements in acceleration and deceleration parameters with flu infection in both young and 
aged mice. Declines in the rate of force development and power output are evident in older 
adults, and more importantly, are strong predictors of functional status and falling risk [40, 41]. 
Thus, many flu-induced functional alterations could be particularly problematic for already at-risk 
older adults.  
Since functional alterations were primarily in the hind limbs, we examined the gastroc, a large 
mixed fiber type muscle, for flu induced alterations in gene expression. Importantly, we 
demonstrated that flu-induced functional decrements were associated with increased 
inflammatory and atrophy gene expression. Both young and aged gastroc had increased 
expression of IL6 and IL6RA by 7 DPI, while IL6RA expression remained elevated at 11 DPI 
only in aged mice. Additionally, TNF expression was only increased in the aged mice. Though 
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the relationship between IL-6 and muscle inflammation and regeneration is not completely clear, 
higher expression of IL-6 and TNF in older adult skeletal muscle is associated with decreased 
muscular strength [42]. Further, it has been demonstrated that older adult humans have 
elevated expression of inflammatory mediators, particularly IL-6 and TNF-α, and dysregulated 
signaling responses that lead to an increased inflammatory milieu and impaired myogenesis 
[43]. This low grade inflammation with aging also impairs postprandial muscle protein synthesis 
[44]. In addition to the common inflammatory mediators in muscle, CXCL10 expression was 
dramatically increased only in the aged mice. While CXCL10 is predominantly associated with a 
Th1 response, it has been recently identified in inflammatory myopathies [45, 46], and secretion 
of CXCL10 from human fetal skeletal muscle cells is induced by treatment with either interferon 
(IFN)-γ or TNF-α [45]. The dramatic increase in CXCL10 expression in the aged mice 
contributes to exaggerated and prolonged gastroc inflammation. Thus, our results agree with 
previous research utilizing chemical [47] or exercise injury [43] and suggests that flu induces 
muscle inflammation in the aged that is heightened and prolonged potentially leading to further 
muscle damage and diminished regeneration.  
Indeed, lingering inflammation in the aged was accompanied by increased and prolonged 
expression of atrophy and protein degradation genes. At 7 DPI both young and aged mice 
gastroc had increased expression of ATROGIN1 and MuRF1; however, at 11 DPI while young 
mice downregulated expression, aged mice atrophy gene expression remained elevated. 
Similarly, both UBB and UBC expression was significantly higher in aged mice at 11 DPI. 
Proteins targeted for degradation that lead to muscle atrophy by atrogin-1 include myogenic 
regulatory factor MyoD and eukaryotic translation initiation factor 3 subunit f (eIF3-f), while 
MuRF1 preferentially targets myosin heavy chains and other myofibrillar proteins, though these 
targets are likely not exclusive to either ligase [30]. Further, in many instances, UBC acts in 
concert with atrogin1 and MuRF-1 through FOXO dependent pathways [48] suggesting that the 
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increased FOXO1 expression may tie together these proteolytic pathways in our flu induced 
muscle atrophy model. Moreover, increased UBC expression has been one of the most 
prominent mRNA increases seen in multiple muscle wasting disorders [49], so it is not 
surprising that UBC expression was the highest correlated gene with weight loss. Indeed, 
multiple atrophy and degradation genes were correlated with flu-induced weight loss, 
suggesting flu-induced weight loss is at least partly due to muscle degradation and atrophy. 
Interestingly, IGF1 was negatively correlated with weight loss in young mice only. Also, in the 
step-wise multiple regression model, the addition of IGF1 accounted for greater explanation of 
variability in weight loss in the young mice; however, this was not observed in the aged mice, 
suggesting anabolic signals are not strong contributors to percent weight loss and recovery in 
aged mice. Indeed, this lack of relationship observed with IGF1 expression in the aged mice is 
likely attributable to anabolic resistance, a more recent concept described as the diminished 
response in aged muscle to many anabolic stimuli including branched chain amino acids and 
exercise [50, 51].  
The observed suppression of positive regulators of muscle mass further tips the protein 
synthesis and protein degradation balance; and these were greater suppressed and prolonged 
in the aged mice. IGF1 and MEF2C suppression was prolonged to 11 DPI in the aged mice, and 
peak suppression of PAX7, MYOD1, and MYOG was greater in aged mice compared to young 
mice. Certainly, IGF1 has been of particular interest in aging research over the years, and low 
circulating levels of IGF1, particularly in combination with elevated IL-6, have been associated 
with decreased muscle strength and increased prevalence of sarcopenia [52]. Thus, flu induces 
these unfavorable responses in muscle tissue itself, predisposing the aged muscle to 
sarcopenic conditions. Surprisingly, no upregulation of positive regulators was evident during 
our time course, suggesting muscle mass may not be recovered. 
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Together our results suggest that flu induces functional decrements, as well as muscle 
inflammation, proteolysis, and atrophy, and that these changes are augmented and prolonged 
with aging. The pathogenesis behind this effect still remains unknown. Despite some studies 
suggesting direct infection of muscle cells [18-20], we showed no viral copies in gastroc muscle 
in vivo throughout the infection. Additionally, myoblasts were not susceptible to a productive 
infection in vitro. Desdouits et al. [19] reported that human myoblasts were less susceptible to 
flu infection than myotubes and response was variable among donors and flu strain, though 
many reports regarding productivity of infection in myoblasts and myotubes are conflicting [18-
20, 53]. Further, it is important to note that mature muscle fibers are much different than 
myoblasts and myotubes, where these immature muscle cells exist only transiently. Satellite 
cells are only present in great quantities in early postnatal development and decrease 
dramatically in adulthood, accounting for 30-35% then 2-7%, respectively, of sublaminal nuclei 
on myofibers [54]. Supporting this, Nevalainen et al. [53] showed that mature muscle fibers do 
not produce viral progeny, though a non-permissive infection occurs. Indeed, in vivo studies 
have shown that a non-permissive infection may occur in the skeletal muscle [25], though this 
seems more likely when intramuscular flu infection models are used [24, 26]. Since we 
performed intranasal infections, similar to the natural route of infection in humans, it is unlikely 
this would occur; however, it is still possible that this non-permissive infection leads to viral 
copies below our detectible limit and direct viral infection, or perhaps the presence of viral 
particles, may contribute to muscle degradation. Collectively, the lack of in vivo evidence to 
suggest that mature muscle fibers are susceptible to infection and that this would actually occur 
during a natural flu infection leads us to conclude further research is necessary to determine the 
mechanism behind flu-induced muscle inflammation and degradation. 
In summary, this chapter and its manuscript is the first to identify in a controlled experiment 
setting flu-induced muscle inflammation and atrophy as well as functional impairment. Further, 
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these effects are prolonged with aging, providing a molecular link to flu infection and disability in 
older adults, together with some initial insights into the mechanism which may underlie aging-
related declines in resilience. We have demonstrated that key inflammatory signals, and key 
ubiquitin proteasome components, both atrogin1 and MuRF1, as well as ubiquitin B and 
ubiquitin C, are upregulated. As it is known that muscle repair is diminished with aging, it is 
likely these muscle losses are not easily recoverable. Thus, future research may be able to 
target these pathways to prevent flu-induced atrophy and potential loss of quality of life in older 
adults. 
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Influenza (flu) infection increases the risk for disability, as well as falls and broken bones in older 
adults. In murine models, flu causes mobility and strength impairments with induction of 
inflammatory and muscle degradation genes that are more pronounced and prolonged with 
aging. As the aging population grows, ways to protect older adults from disability are 
increasingly important. Here, we examined if vaccination could reduce flu-induced muscle 
decrements with aging. Young and aged mice were vaccinated with recombinant flu 
nucleoprotein (NP), infected with flu virus, and muscle parameters were measured following 
infection. We determined that vaccination provides almost complete protection from functional 
decrements, muscle gene expressions alterations, and morphological damage in young mice 
and partial protection from these muscular declines in aged mice. Similarly, vaccination 
improved protection from lung localized and systemic inflammation in aged mice. Despite 
documented decreased vaccine efficacy with aging, vaccination still provided partial protection 
to aged mice and represents a potential strategy to prevent flu-induced disability with aging. 







Influenza (Flu) and pneumonia are the seventh leading cause of death among older adults in 
the US with 90% of all flu-related deaths occurring in late life [1]. Equally compelling from a 
clinical and public health perspective, but less well understood, is the relationship between flu 
infection and disability. Older adults have a greatly increased risk of both progressive and 
catastrophic disability following flu infection [2, 3], including a greater risk of falls and broken 
bones [4]. Nevertheless, mechanisms by which flu infection contributes to this risk of disability 
remain unknown and unexplored, resulting in missed opportunities for the discovery of 
interventions designed to prolong function and independence in late life. Flu infections, even in 
uncomplicated cases, have some degree of muscle involvement with myalgia being a common 
symptom [5]. We previously reported that flu infection, which by its very nature is limited to 
pulmonary epithelial cells, results in mobility and strength impairments and increased markers of 
muscle atrophy in a well-established murine model of infection. Moreover, these effects are 
more pronounced and prolonged with aging, providing a molecular link between flu infection and 
disability in older adults [6]. The pathogenesis of this interaction is unknown and little 
information exists detailing the systemic impact of flu infection and how it changes with aging. 
Here we investigate if prior immunity can prevent the muscular ailment. Our goal is to provide 
translationally relevant insight on potential ways to protect older adults from flu-induced 
functional decrements and muscle atrophy. 
The average flu-related mortality is between 20k-40k people annually [7]. Flu vaccination 
substantially reduces mortality in humans [7]. Indeed, a 1% increase in total vaccination rate 
would result in an estimated 800 fewer deaths [7]. Through decades of research, it is clear that 
vaccination improves the humoral and cellular functions of the immune system in response to 
flu. Inactivated and recombinant flu vaccines induce robust antibody and CD4+ T cell 
responses. Neutralizing antibodies work to prevent infection, while non-neutralizing antibodies 
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facilitate viral clearance via mechanisms such as antibody-dependent cell-mediated cytotoxicity 
[8]. This results in faster clearance of flu and less severe illness. Previous vaccination studies 
from our lab [9] emphasized the two-pronged protection of flu nucleoprotein (NP) vaccination 
with antibody and lung-homing T cell effector generation to provide non-neutralizing protection. 
Though general vaccination efficacy is reduced with aging, inflammation and lung viral copies 
were reduced in both young and aged mice with NP vaccination.  
While many benefits of vaccination have been previously reported, the effects of vaccination on 
muscle function and overall muscle quality, specifically in the more vulnerable aged population 
has not been explored. Indeed, muscle integrity and quality are key components when 
considering recovery, resilience, and prevention of physical disability in the aging population. 
Here, we investigated how non-neutralizing immunity induced by vaccination with NP impacts 
the muscular decrements observed during flu infection. NP vaccination induces a protective 
heterosubtypic antibody response in young mice [10, 11], and reduces lung inflammation and 
susceptibility to secondary bacterial infection following primary flu infection [12]. Previously we 
showed that NP vaccination of aged mice protected them from death following flu infection, but 
did not protect from flu-induced weight loss [9]. Thus, we hypothesized that NP vaccination 
would mediate protection in muscle through reduction in flu-induced inflammation. 
Skeletal muscle is a complex tissue consisting of many different cell types, as well as different 
muscle fibers. The four main fiber types in murine skeletal muscle are based on different muscle 
myosin heavy chains (MyHC). MyHC I fibers are considered slow twitch fibers while, MyHC IIA, 
IIX, and IIB fibers are fast twitch fibers [13, 14]. Fiber areas and muscle cross sectional areas in 
skeletal muscles of mice differ with fiber sizes increasing in the order type I < IIA < IIX < IIB [13]. 
Typical mouse skeletal muscle is 77% MyHC IIB [14]. With aging, type IIB and IIX fibers have 
impaired regeneration capacities in response to immobilization atrophy [15]. Translationally, fast 
twitch fibers control balance, strength, and numerous other necessary functions in humans and 
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rodents.  In human aging, there is marked muscle atrophy, along with a decrease in total 
number of fibers with preferential loss of type II muscle fibers [17]. Indeed, the change in 
composition to greater slower-contracting isoforms leads to symptoms consistent with 
denervation [16]. In addition to the quantitative loss, there is also a qualitative decline in muscle 
in terms of specific force (force generation normalized for muscle cross-sectional area), 
dysfunctional proteins, and other age-associated deficiencies [18, 19, 20, 21]. Typically, fast-
twitch muscle fibers are more vulnerable to degeneration and more sensitive to inflammation 
[22, 23, 24]. Importantly, the decline in muscle strength from type II fiber atrophy and loss can 
lead to sarcopenia, which increases risk of loss of activities of daily living. Since clinically there 
is an increase in loss of activities of daily living following flu infection and type II fibers are more 
sensitive to age-related loss and inflammatory stimuli, we hypothesize that flu will most severely 
affect type II fibers. 
In this report, we examine the impact of NP vaccination on muscular function and quality in a 
preclinical model of flu infection with aging. As we have previously shown, NP vaccination leads 
to reduced inflammatory mediators in the bronchoalveolar lavage (BAL), high titers of NP-
specific antibody, and improved lung viral clearance [9]. Here, we show that vaccination was 
able to preserve the function of young and aged mouse grip strength, gait kinematics, and 
voluntary mobility parameters, as well as reduce inflammation within the skeletal muscle and 
prevent morphological disruption and type II muscle atrophy. Thus, our results point to a novel 
finding that despite reduced vaccine efficacy with aging, vaccination provides protection from 







Mice. Young (2.5-4-month-old) C57BL/6 male mice were purchased from Jackson Laboratories 
or obtained from the National Institute on Aging. Aged (19-22-month-old) C57BL/6 male mice 
were obtained from the National Institute on Aging rodent colony. All mice were housed in a 
climate controlled environment with 12:12 light:dark cycle and fed standard rodent chow and 
water ad libitum. All mice were cared for in accordance with the recommendations in the Guide 
for the Care and use of Laboratory Animals of the National Institutes of Health. All procedures 
were approved by the University of Connecticut Medical School IACUC, protocol number 
100705. Recumbent mice and mice that lost more than 30% body weight were considered 
moribund and euthanized. All mice underwent gross pathological examination at time of 
sacrifice and animals with obvious pathology were excluded from the study. 
Viral infection. Mice were anesthetized with isoflurane and intranasally inoculated with 50 ul of 
500 EID50 of influenza virus A/PR/8/34 (PR8). Mice were weighed daily to monitor infection 
progression. At time points indicated, whole lung tissue was homogenized and RNA was 
isolated via TRIzol/chloroform extraction per manufacturer’s protocol (Ambion by Life 
Technologies, Naugatuck, CT and Sigma Aldrich, Natick, MA, respectively). RNA was reverse 
transcribed with iScript cDNA synthesis Kit (Bio-Rad Laboratories, Inc., Hercules, CA) and flu 
viral copies were detected via reverse transcription quantification PCR of flu acid polymerase 
(PA) as previously described (58). 
Vaccination. Recombinant A/PR/8/ influenza nucleoprotein (NP) was generated by the Protein 
Expression Core at UConn Health. Immunizations were prepared using NP protein and Imject 
Alum (Thermo Scientific) at 1:1. Injections were administered intraperitoneal at a concentration of 
30ug NP in 100uL per mouse. Control mice were given 100uL PBS. Previous studies in our 
laboratory showed no differences between PBS control and PBS/alum control [9]. Mice received 
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one dose of vaccination or control at 30 days and a second dose at 20 days prior to influenza 
infection [10].  
Antibody Titers. 96-well plates were coated with recombinant A/PR/8/34 influenza NP 
(generated by UConn Health Protein Expression Core). Serum samples were serial diluted 
(1:10 to 1:1x108). Anti-NP IgG titers in serum were the determined using anti-mouse IgG-HRP 
(Southern Biotech, Birmingham, Alabama) and o-phenylenediamine (Sigma, Natick, 
Massachusetts) buffered in hydrogen peroxide. Samples were read in duplicate (490nm, Bio-
Rad iMark microplate reader, Hercules, California). Antibody titers were determined by the last 
serum dilution with an optical density above background.  
Gastrocnemius Reverse-Transcription quantitative PCR (RT-qPCR). At the time points indicated 
for gastrocnemius gene expression, mice were fasted with the exception of water for 4-6 hours 
prior to sacrifice to minimize potential confounding results due to postprandial muscle protein 
synthesis. The gastrocnemius muscle was dissected and placed in RNAlater (Qiagen Inc., 
Germantown, MD) overnight at 4⁰C. RNAlater was removed and gastrocnemius was frozen at -
80⁰C until RNA extraction. The muscle was homogenized and RNA was extracted via 
TRIzol/chloroform extraction per manufacturer’s instructions (Ambion by Life Technologies and 
Sigma Aldrich respectively). RNA quantity and quality were assessed with Nanodrop 2000c 
(Thermo Scientific, Waltham, MA) and was reverse transcribed via iScript Advanced cDNA 
synthesis Kit (Bio-Rad Laboratories, Inc., Hercules, CA). RT-qPCR was performed using 
predesigned commercially available primers (Bio-Rad Laboratories, Inc.). Gene expression was 
calculated via a modified Pflaffl method utilizing multiple reference genes (RPS18 and TBP, 
which showed the least variability between conditions and thus suitable reference genes as 
previously shown (6)) and normalized to the unvaccinated uninfected young mice to give 
comparable changes.  
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Multiplex Protein Analysis. Bronchiolar lavage fluid (BAL) was collected by flushing lungs with 1 
ml PBS. Supernatant was collected after centrifugation and assayed for cytokine and 
chemokine content. Similarly, blood was collected via cardiac puncture, allowed to clot at room 
temperature, and the resultant serum was assayed for cytokine and chemokine content. 
Gastrocnemius muscle was dissected from each mouse and homogenized in Tissue Protein 
Extraction Reagent (Thermo Scientific, Bedford, MA)) supplemented with 5mM EDTA 
(Invitrogen, Carlsbad, CA) and Protease/Phosphatase Inhibitor Cocktail (Thermo Scientific)). 
Debris was removed via centrifugation and total protein content was determined using a 
Pierce™ BCA Protein Assay Kit (Thermo Scientific).  
Voluntary locomotor activity. Spontaneous voluntary locomotor activity was measured via open 
field test at time points indicated. All tests were performed between 7-9am to control for diurnal 
variations. Following acclimation to the dim-lit testing room (at least 1 hour), mice were placed in 
the center of the photobeam activity system-open field (PAS-OF, 16”x16”x15” acrylic animal 
enclosure, San Diego Instruments, San Diego, CA) and their activity was recorded for 20 
minutes. The first 5 minutes was excluded as this is generally considered to be exploratory 
behavior rather than general voluntary locomotor activity. The number of beam breaks per 
minute during the last 15 minutes was then used to assess voluntary locomotor activity. 
Grip strength. Grip strength was determined by using a grip strength meter BIOSEB In Vivo 
Research Instruments, Pinellas Park, FL). Briefly, mice were permitted to grab onto a T-shaped-
bar and pulled horizontally by the tail until they released their grip. The force (grams) read by 
the force meter at the release of the mouse’s grasp was averaged by their mass (grams) on that 
day and compared to their pre-infection results. The same researcher performed all testing to 
minimize variability.  
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Gait analysis. Gait analysis was performed using the DigiGait instrument (Mouse Specifics, Inc. 
Quincy, MA) and software (DigiGait Imager 4.0.0 and DigiGait Analysis 11.5, Mouse Specifics, 
Inc). The DigiGait instrument consists of a clear treadmill with a high-speed camera mounted 
underneath that collects images at 147 frames per second for high resolution of postural 
temporal gait parameters. Mice run within a 2-inch-wide acrylic running chamber at set speeds. 
The ventral plane videos are analyzed with the DigiGait software which identifies portions of the 
paw that are in contact with the treadmill belt to produce both postural and kinematic gait 
parameters. Mice were introduced to the DigiGait system at a low speed (10cm/sec) briefly (30 
seconds) prior to the initial testing. Mice were allowed to acclimate to the dim-lit room for 1 hour 
prior to each testing period and all tests were performed between 8-10 am. Mice ran at the 
testing speed (16cm/sec, as previously optimized (6)) until approximately 5 seconds of 
consecutive walking was recorded and this video segment was analyzed via DigiGait software.  
Histology. The gastrocnemius muscle was carefully dissected and blotted on a Kim Wipe before 
being placed in a cryomold, embedded in Optimal Cutting Temperature (OCT ThermoScientific 
Inc., Waltham, MA) and frozen in liquid nitrogen cooled isopentane. Samples were stored at -
80°Celsius freezer until sectioning. 10um thick muscle cross sections were mounted on charged 
slides (Superfrost Plus Glass Slides, ThermoScientific Inc., Waltham, MA) for histological 
analyses. Standard Hematoxylin and eosin (H&E) staining was performed and imaged at 20X. 
H&E images were blindly scored by multiple evaluators utilizing a rubric adapted from the 
literature (33, 34). The rubric was based on two criteria, 1) infiltration of nuclei, and 2) 
architecture disruption and tissue damage. Each criterion was independently scored from 0-3 
and combined for a total score that ranged 0-6.  
Fiber Type Staining. Primary antibodies for muscle fiber types were acquired from the 
Developmental Studies Hybridoma Bank (DSHB) at the University of Iowa: myosin heavy chain 
type I (DSHB, BA-D5), myosin heavy chain type IIA (DSHB, SC-71, and myosin heavy chain 
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type IIB (DSHB, BF-F3). Secondary antibodies Alexa Fluor 647 (Invitrogen Carlsbad, CA), Alexa 
Fluor 488 (Life Technologies St. Petersburg, FL), and Alexa Fluor 555 (Life Technologies St. 
Petersburg, FL) were utilized, respectively. Nuclei were stained with Hoechst 33342 (Life 
Technologies St. Petersburg, FL). Stained slides were imaged via confocal microscopy (Zeiss 
LSM 880, Peabody, MA) Cross sectional area was quantified using ImageJ (NIH, Bethesda, 
MD).  
Statistical analysis. All data analyzed via two-way (treatment x age) ANOVA with Bonferroni 
post hoc corrections. Significant differences comparing (*=p<0.05) to baseline (NoVax/NoFlu) 
age-matched controls, comparing (#=p<0.05) to unvaccinated infected (NoVax/Flu) age-
matched controls, and comparing (brackets=p<0.05) between groups/ages within a condition.  
 
RESULTS 
Prior vaccination prevents body mass loss and accelerates viral clearance during flu infection. 
Utilizing established methods from our lab [9] and others [10, 11], young (2.5-4 months) and 
aged (19-22 months) mice were vaccinated with NP/alum (Vax) or PBS control (NoVax) and 
infected with a sublethal dose of PR8 influenza virus (Fig S1). In unvaccinated mice, infection 
led to greater weight loss (Fig1A) and higher flu copy number in the lung (Fig1B) in both young 
and aged mice when compared to vaccinated groups. Young vaccinated mice were protected 
from weight loss and had accelerated viral clearance, while aged vaccinated mice only had 
partial protection. At 9 days post infection (DPI), the vaccinated aged mice follow similar trends 
as unvaccinated young mice. We have previously shown that aged mice suffer greater and 
prolonged weight loss compared to young mice [6]. Similarly, young mice are more resilient than 
aged mice with vaccination. Despite similar peak virus levels in the lung at 7 DPI, vaccinated 
young and aged mice clear the virus faster than their unvaccinated controls (Fig1B), though 
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differences between young and aged mice are still evident. Importantly, vaccination induced 
increased serum anti-NP IgG antibodies (Fig1C), supporting the efficacy of the vaccination. 
Overall, the NP/Alum vaccination hastens viral clearance while reducing body mass losses in 




Figure 1. The NP/Alum vaccination hastens viral clearance while reducing body mass loss. Young 
and aged C57BL/6 mice were vaccinated with NP/Alum or PBS before being intranasally infected with 
500 EID50 of PR8 influenza. A) The percent body mass loss graphed over the course of the experiment 
and bar graph of day 9 post infection differences (n=10-15/group). B) Influenza acid polymerase (PA) 
copy number determined by RTqPCR of mouse lungs at given time points (n=5-6/group). C) IgG titer for 
influenza nucleoprotein assayed via ELISA of mouse serum (n=5-6/group). Data analyzed via two-way 
ANOVA with Bonferroni post hoc corrections comparing to NoVax/NoFlu age-matched controls 
(*=p<0.05), comparing to NoVax/Flu age-matched controls (#=p<0.05), and comparing between day post 
infection/ages (brackets=p<0.05).  
Prior vaccination protects muscular function during flu infection. As we have shown previously 
[6], flu infection without prior vaccination leads to functional decrements in voluntary locomotor 
activity, grip strength, and gait kinematics. Importantly, prior vaccination prevents these 
decrements in young mice and either prevents or reduces these decrements in aged mice. 
Postural gait parameters were assessed utilizing DigiGait at 7 DPI. Hind midline distance 
decreased with infection in both young and aged unvaccinated mice, while this decrease was 
prevented with vaccination only in young mice (Fig2A). Conversely, fore limb midline distance 
was only decreased in unvaccinated aged mice and vaccination prevented this decrease (Fig 
S2A). Thus, mice have a narrower hind stance during flu infection and vaccination was not able 
to prevent this narrowing in aged mice, however, the narrowing of the fore limb stance was 
protected with vaccination in aged mice. Hind and fore stride length increased with infection in 
aged unvaccinated mice, while this increase was prevented with vaccination in young and aged 
mice (Fig2B & Fig S2B). Kinematic gait parameters in the hind and fore limbs such as stride 
frequency (Fig2C & Fig S2C), time propelling (Fig2D & Fig S2D), stance time (Fig2E & Fig 
S2E), time in stride (Fig2F & Fig S2F), time in swing (Fig2G & Fig S2G) also followed similar 
trends in aged mice. In contrast, young mice experienced no kinematic gait changes in their 
hind (Fig2C-G) or fore (Fig S2C-G) limbs during infection. Importantly, aged mice had increased 
time in the propel, stance, stride, and swing phases during infection, which was only partially 
protected with vaccination as some decrements were still evident in aged vaccinated mice 
(Fig2C-G). Overall, these results suggest that flu infection leads to a narrower stance and 
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slower gait movements in aged mice and that vaccination preserved baseline gait parameters 
and protected aged mice from many flu-induced changes.  
Similarly, vaccination significantly protected both young and aged mice from decreased 
voluntary activity at 8 DPI, assessed by open field, compared to their unvaccinated counterparts 
(Fig2H). Infection without prior immunity led to an approximate 50% decrease of their initial 
voluntary activity by 8 DPI. Vaccinated mice were protected from this decrease, however aged 
vaccinated mice did not perform as well as their young vaccinated counterparts. Additionally, 
grip strength, as measured by a grip strength meter and normalized to pre-infection levels, was 
preserved in vaccinated mice, while unvaccinated mice had decreased strength (Fig2I) in both 
young and aged groups.  
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Figure 2. Vaccination against influenza reduced flu-induced functional decrements in voluntary 
locomotor activity, grip strength, and gait kinematics. Young and aged C57BL/6 mice were 
vaccinated with NP/Alum or PBS before being intranasally infected with 500 EID50 of PR8 influenza. Mice 
were acclimated to testing prior to infection and tested for functional performance at designated time 
points. A-G) Gait parameters were assessed utilizing DigiGait 7 days post infection (n=8-15/group). H) 
Spontaneous voluntary activity was assessed via the open field test at 8 days post infection (n=10-
15/group). I) Grip strength was determined by using a grip strength meter at day 8 post infection (n=10-
15/group). Data analyzed via two-way ANOVA with Bonferroni post hoc corrections comparing to 
NoVax/NoFlu age-matched controls (*=p<0.05), comparing to NoVax/Flu age-matched controls 
(#=p<0.05), and comparing between ages within a condition (brackets=p<0.05). 
 
Vaccination mitigated alterations in cytokine/chemokine inflammatory milieu. Proinflammatory 
cytokine and chemokines (IFN-γ, IL-6, and CXCL10) were assessed in the BAL from young and 
aged mice post infection and they followed similar trends (Fig3A-C and Fig3F-H) with increased 
levels by 7 DPI in unvaccinated infected mice. Young vaccinated mice only showed modestly 
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increased levels of proinflammatory signals during infection and returned to baseline levels by 9 
DPI. Vaccination did not mitigate the peak levels of inflammation in aged cohorts but did hasten 
the resolution of inflammation by 9 DPI. In sum, vaccination prevented prolonged inflammation 
in aged BAL, but did not reduce peak inflammation at 7 DPI. Type 2 cytokines (IL-4 and IL-10) 
are generally considered anti-inflammatory and counteract inflammatory cytokines (Fig3D-E & 
Fig3I-J) [25, 26]. IL-4 increased with infection, peaking at 7 DPI, and was higher in vaccinated 
mice compared to their unvaccinated age-matched counterparts (Fig3D & Fig3I). Interestingly, 
only aged vaccinated mice still had elevated IL-4 at 9 DPI (Fig3I). IL-10 peaked in all groups at 
7 DPI and returned to close to baseline levels by 9 DPI (Fig3E & Fig3J). Interestingly, 
vaccination in aged mice led to significantly increased in IL-10 at 7 DPI, compared to the 
unvaccinated aged mice (Fig3J), while vaccinated young mice had lower IL-10 levels at 7DPI 
compared to unvaccinated young mice (Fig3E). It is likely the reduced inflammation in the young 
vaccinated mice did not require strong anti-inflammatory responses at that time point. In totality, 
vaccination reduced peak inflammation and limited prolonged inflammation in the BAL of young 
and aged mice while also promoting IL-4 and IL-10 production in aged mice.  
Systemic inflammation, as measured by serum cytokines and chemokines, followed a similar 
trend as in the BAL. Flu infection led to increased serum IFN-γ, IL-6, and CXCL10 at 7 DPI in all 
groups (Fig3K-M & Fig3P-R). Vaccination reduced serum IFN-γ levels at 7 DPI in both young 
and aged compared to unvaccinated controls. Conversely, serum IL-6 was elevated by 5 DPI in 
all groups (Fig3L & Fig3Q). Vaccinated mice began to decrease levels of IL-6 by 7 DPI, while 
unvaccinated young mice continued to increase at 7 DPI before returning to baseline levels 
(Fig3L) and unvaccinated aged mice levels remained elevated at 9 DPI (Fig3Q). Serum 
CXCL10 increased with infection in all groups (Fig3M & Fig3R), with only minor increases in the 
young vaccinated mice. Conversely, aged vaccinated mice followed similar trends to the 
unvaccinated young mice with increases at 7 DPI that returned to near baseline levels by 9 DPI 
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(Fig3M & Fig3R). Similar to IL-6, serum CXCL10 continued to rise in unvaccinated aged mice 
with peak levels seen at 9 DPI. Thus, the unvaccinated aged group had prolonged IL-6 and 
CXCL10 elevation at 9 DPI compared to other groups. Prior vaccination resulted in increased 
serum IL-4 at 7 and 9 DPI in young mice only (Fig3N). Serum IL-10 was increased at 7 and 9 
DPI in young vaccinated mice (Fig3O), but only at 9 DPI in aged vaccinated mice (Fig3T). 
Importantly, serum IL-4 and IL-10 did not change in both young (Fig3N-O) and aged (Fig3S-T) 
unvaccinated mice, suggesting vaccination speeds up systemic anti-inflammatory signals. In 
sum, vaccination reduced prolonged systemic inflammation and provided modest increases in 
anti-inflammatory signals in aged mice. It is known that muscle atrophy can be triggered by 
external stress signals and overall inflammation status of an individual. Thus, we hypothesized 
that by limiting systemic flu-induced inflammation with vaccination we could reduce the negative 
impact of flu on muscle.   
Figure 3. Vaccination reduces flu-induced cytokines and chemokines in the BAL and Serum. 
Young and aged C57BL/6 mice were vaccinated with NP/Alum or PBS before being intranasally infected 
with 500 EID50 of PR8 influenza. A-J) Bronchoalveolar Lavage (BAL) was collected from mice at time of 
sacrifice as described in methods. The BAL was then analyzed via Millipore chemokine/cytokine Multiplex 
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25-plex for the analytes (n=16-21). K-T) Serum was collected from mice at the time of sacrifice as 
described in methods. The serum was later analyzed via Millipore chemokine/cytokine Multiplex 25-plex 
for the analytes listed (n=16-21). Data analyzed via two-way ANOVA with Bonferroni post hoc corrections 
comparing to NoVax/NoFlu age-matched controls (*=p<0.05) and comparing to NoVax/Flu age-matched 
controls (#=p<0.05). 
 
Vaccination mitigates negative skeletal muscle gene and protein expression changes. To 
determine if vaccination-related reduction in BAL and serum inflammation would be associated 
with reduced negative changes in skeletal muscle, we first examined muscle gene and protein 
expression. We have previously shown that flu infection results in dramatic increases in muscle 
atrophy genes [6]. Here, we found that vaccination mitigates flu-induced changes in skeletal 
muscle gene expression (Fig4A-J) and protein expression in gastrocnemius (Fig4K-T). 
Vaccination in both young (Fig4A) and aged (Fig4F) mice prevents MuRF-1 expression 
(considered a major regulator of skeletal muscle atrophy). Similarly, Ubiquitin C (UBC) 
upregulation is reduced with vaccination in young mice (Fig4B), with minor upregulation evident 
in aged vaccinated mice at 9 DPI (Fig4G). Conversely, unvaccinated aged mice show dramatic 
upregulation at 9 DPI (Fig4G). This suggests that vaccination completely protects young mice 
from muscle atrophy gene expression changes, while only partially protecting aged mice. Insulin 
Growth Factor-1(IGF-1), a positive regulator of the mTOR pathway that promotes muscle 
hypertrophy and suppresses atrophy gene expression [27, 28], was surprisingly not statistically 
significantly decreased, but was trending significance in unvaccinated infected groups 7 DPI 
(young NoVax/Flu p=0.08 and aged NoVax/Flu p=0.09) (Fig4D and Fig4I). The aged vaccinated 
mice had an increase at 9 DPI (Fig4D and Fig4I). It is possible that a decrease in IGF-1 was 
missed in the unvaccinated groups during the experimental time course. It is also possible that 
an increase in IGF-1 was not observed in the young vaccinated mice due to decreased damage 
and need for any muscle repair. Myoblast determination protein 1 (MyoD), a critical factor 
regulating satellite cell proliferation and muscle repair, was downregulated in young and aged 
unvaccinated mice at 7 DPI (Fig4E and Fig4J), but remained downregulated at 9 DPI only in 
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unvaccinated aged mice compared to their aged vaccinated counterparts (Fig4J). Conversely, 
vaccination protected both young and aged mice from downregulation of MyoD (Fig4E and 
Fig4J). Thus, vaccination promoted positive muscle regulators of both young and aged mice at 
later time points, suggesting accelerated healing from flu-induced muscle damage.  
Since it is known that the inflammatory milieu of skeletal muscle affects muscle atrophy and 
muscle repair pathways [6], we next examined how vaccination impacts the flu-induced cytokine 
and chemokine protein expression in the gastrocnemius muscle. Not surprisingly, baseline 
differences existed in multiple cytokines and chemokines [29, 30, 31, 32]. IFN-γ only 
significantly increased in unvaccinated aged mice at 7 DPI and unvaccinated young mice at 9 
DPI, while vaccinated groups are protected from this change (Fig4K and Fig4P). Conversely, IL-
6 changes are not vaccination dependent. Young mice have increased IL-6 at 9DPI (Fig4L), and 
aged mice have increased IL-6 at 7 DPI irrespective of vaccination status (Fig4Q). CXCL10, a 
chemokine for recruiting type 1 inflammatory cells, remained unchanged in young unvaccinated 
and vaccinated mice (Fig4M). Conversely, CXCL10 is elevated at 7 DPI in both unvaccinated 
and vaccinated aged mice, but to a greater degree in the unvaccinated mice (Fig4R). By 9 DPI, 
only unvaccinated aged mice have elevated CXCL10, suggesting vaccination prevented 
prolonged CXCL10 expression (Fig4R). In totality, since IL-6 actions are pleiotropic in skeletal 
muscle, it is hard to distinguish the pathology of the discordant increases with age. Importantly, 
however, IL-6 in the aged muscle is increased at the same time as IFN-γ and CXCL10. This 
suggests a more inflammatory environment. Conversely in vaccinated young mice, there is no 
simultaneous IFN-γ or CXCL10 increase, possibly suggesting an appropriate signal for 
myogenesis. On the anti-inflammatory side, IL-4 and IL-10 were both increased in aged mice at 
baseline (NoVax/NoFlu) compared to young mice (NoVax/NoFlu) (Fig4S-T). IL-4 increased 
steadily in both unvaccinated and vaccinated aged mice and was elevated at 7 DPI and 9 DPI 
with greater levels in the vaccinated aged group (Fig4S). In contrast, young mice did not exhibit 
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any changes in IL-4 irrespective of vaccination (Fig4N). IL-10 was increased in all groups except 
the unvaccinated aged mice at 9 DPI (Fig4O and Fig4T). It is likely that the lower levels of 
inflammatory signals in young mice did not require a robust anti-inflammatory response as 
evident by the low levels of IL-4 (Fig4N). Furthermore, this is corroborated by the gene 
expression changes at this time showing that young mice have decreased muscle atrophy gene 
expression when compared to aged mice with or without vaccination. In totality, vaccination 
prevents muscle atrophy gene expression changes in young mice and reduces muscle atrophy 
gene expression in aged mice, which is accompanied by similar changes in the inflammatory 
milieu including reduced pro-inflammatory signals and increased anti-inflammatory signals in the 
aged vaccinated mice.  
Figure 4. Vaccination reduces flu-induced skeletal muscle gene expression and protein 
expression in gastrocnemius. Young and aged C57BL/6 mice were vaccinated with NP/Alum 
or PBS before being intranasally infected with 500 EID50 of PR8 influenza. A-J) Vaccination 
reduced changes in gastrocnemius muscle gene expression (n=10-19). K-T) Vaccination 
altered the kinetics of muscle cytokine, chemokine, and myokine levels (n=4-6). Data analyzed 
via two-way ANOVA with Bonferroni post hoc corrections comparing to NoVax/NoFlu age-




Vaccination reduces muscle morphological changes and fast twitch fiber atrophy. To determine 
if the changes in gene expression and inflammatory milieu resulted in detectable changes in 
muscle morphology and architecture, we investigated gastrocnemius histology. Cross-sections 
of the gastrocnemius muscle of unvaccinated and vaccinated infected mice at 9 DPI were 
hematoxylin and eosin (H&E) stained and blindly scored on multiple histological parameters 
adapted from the literature (33, 34). Flu infection increased architectural damage and cellular 
infiltration in young and aged unvaccinated mice (Fig5A-B). Importantly, vaccination mitigated 
these changes in both age groups (Fig5A-B & Fig S3A-B). Similarly, total H&E scores showed 
pronounced protection from morphological changes with vaccination (Fig5B). Further 
immunohistochemistry revealed that flu infection induced fiber specific atrophy, where type IIB 
fibers were the only ones detrimentally affected during infection (Fig5C-D & Fig S3C). Type IIB 
fibers lose one third of their cross-sectional area by 9 DPI in both unvaccinated groups (Fig5C & 
Fig5D), while vaccination prevented these losses. Type I, IIA, and IIX muscle fibers were not 
severely impacted during flu infection. This agrees with the general consensus that MyHC IIB is 
more sensitive to inflammation and other stressors [22, 23, 24].  
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Figure 5. Vaccination reduces muscle morphological changes and fast twitch fiber atrophy. Young 
and aged C57BL/6 mice were vaccinated with NP/Alum or PBS before being intranasally infected with 
500 EID50 of PR8 influenza. Mice were sacrificed at 9 days post infection and gastrocnemius muscle was 
harvested for histological analyses. A) Represented Hematoxylin and Eosin (H&E) staining of 
gastrocnemius skeletal muscle from uninfected (left), unvaccinated/infected (middle), and 
vaccinated/infected (right) 9 DPI aged mice. Scale bars are 100 μm. B) Quantification (detailed in 
methods) of muscle morphological changes (n=3-5). C) Muscle cross-sectional area via 
immunofluorescent staining from uninfected (left), unvaccinated/infected (middle), and 
vaccinated/infected (right) 9 DPI aged mice. Colors: myosin heavy chain I (red), myosin heavy chain IIA 
(green), myosin heavy chain IIB (yellow), myosin heavy chain IIX (no stain), nuclei (cyan). Scale bars are 
100 μm.  D) Quantification of fiber type cross-sectional area (n=3-5). Data analyzed via two-way ANOVA 






With age, the immune response to flu infection diminishes resulting in slower viral clearance and 
increased lung inflammation [9]. Indeed, unvaccinated aged mice follow this pattern in our 
study. Aged mice are typically slower to clear virus and exhibit higher and prolonged 
inflammatory cytokines in the BAL and serum when compared to young. This lingering 
inflammation in response to flu is associated with dramatic changes in mouse mobility, gait 
kinematics, strength, and other functional parameters. Interestingly, vaccination in aged mice 
reduced weight loss, but did not prevent it as in young mice. Vaccination also resulted in faster 
viral clearance and improved anti-IgG antibody titers in both young and aged mice. In older 
adults, flu infection increases the susceptibility to secondary infection and other flu 
complications [35]. Thus, ways to better control viral infection, especially in older adults, are a 
clinically important goal. Here, we show that vaccination not only controls viral loads in the lung, 
but also prevents flu-induced muscle dysfunction, both on a functional and molecular level. We 
believe that the impact of flu infection on muscle may directly predispose older adults for 
catastrophic disability and sarcopenia as well as increase risk of falls and other musculoskeletal 
injuries. Thus, we have identified vaccination as a proactive protective preventative measure 
with the potential to increase resilience in older adults.  
We previously demonstrated that flu infection leads to prolonged muscular deficits, both 
functionally and molecularly, with more pronounced changes in aged mice compared to young 
mice [6]. This provided a molecular link for the increased risk of disability in older adults 
following a flu infection seen clinically. Here, we investigated the clinical significance of prior 
immunity to protect against flu-induced muscle decrements. Indeed, we have shown that 
vaccination mitigates functional losses. Importantly, vaccination reduces the decrements in 
voluntary mobility, grip strength, and gait kinetics observed with flu infection in aged mice.  
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Vaccination also protected young and aged mice from increased and prolonged inflammation 
systemically. Some level of inflammation is necessary to clear flu virus from the lungs. In fact, 
without IL-6, mice die from flu infection [36, 37]. Similarly, without adaptive immune trafficking to 
the lung via ligands such as CXCL10, there is not proper viral clearance [38]. We emphasize 
here that prolonged inflammatory responses exacerbate the damage to skeletal muscle. IFN-γ 
is primarily produced by immune cells and has been known to trigger CXCL10 expression [38, 
39, 40]. The production of these inflammatory cytokines and chemokines were not completely 
prevented in our vaccinated aged mice, but their prolonged elevation was mitigated. Vaccinated 
groups also had higher levels of IL-4 and IL-10 in the BAL, serum, and skeletal muscle. While 
serum IL-4 and IL-10 play a role in IgG antibody responses [41], they also act to suppress the 
systemic inflammation seen during peak infection. In fact, we see increases in IL-4 and IL-10 in 
the BAL and serum at 7 and 9 DPI as viral titers are diminishing and the lung is polarized 
towards type-2 regenerative response. These factors are also crucial to skeletal muscle 
regeneration. While IL-6, IL-1β, and TNF-α have all been associated with skeletal muscle 
atrophy [42, 43, 44, 45] and contribute to a catabolic environment which over time reduces 
muscle function in humans and rodents, IL-4 and IL-10 have crucial roles in muscle repair and 
regeneration. IL-4 is a molecular signal that controls myoblast fusion with myotubes. Indeed, 
muscle cells lacking IL-4 signaling/receptors form normally, but are reduced in size and 
myonuclear number [46]. Absence of IL-10 is associated with elevated IL-6, IL-1β, and TNF-α 
expression in response to lipopolysaccharide (LPS) in skeletal muscle, with aging further 
exacerbating these responses [47]. Similarly, both IL-4 and IL-10 trigger changes in 
macrophage phenotype that promote muscle growth and regeneration [48, 49]. In fact, muscle 
growth and regeneration are greatly slowed by loss of IL-10 [49]. Our research confirms that flu 
infection induces a pro-inflammatory environment in the muscle and that vaccination can 
increase the anti-inflammatory milieu with IL-4 and IL-10.  
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This more anti-inflammatory environment generated upon vaccination corresponded with both 
improved muscle gene expression and preserved muscle morphology. Fast twitch muscle fibers 
(mainly MyHC IIB) are most sensitive to inflammation [22, 23, 24] and we found that they were 
significantly decreased in size by 9 DPI in unvaccinated young and aged mice. Similarly, 
histology scores showed poor architecture and increased cellularity at this time point in 
unvaccinated mice. Importantly, these same mice had increased expression of the atrophy 
genes Murf-1 and UBC, as well as pronounced functional deficits. Vaccination reduced or 
prevented all of these declines with preserved type IIB fiber cross sectional area and 
morphology, as well as reduced expression of atrophy genes and less impairment of muscle 
function. Indeed, there was no visible difference between naïve controls and vaccinated mice of 
both age groups. Additionally, we observed upregulated skeletal muscle IGF1 in vaccinated 
aged mice at 9 DPI. In vitro, IGF-1 stimulation of C2C12 myotubes increased mouse type IIB 
MyHC mRNA, suggesting IGF-1 has a role in MyHC IIB gene expression [50]. Further, 
overexpression of IGF-1 for 9 months in extensor digitorum longus (EDL) muscles (primarily 
composed of type IIB fibers) prevented muscle atrophy and loss of type IIB fibers in aged mice 
[51]. This suggests vaccination is also promoting positive muscle signals to prevent loss of 
function. Our research clearly highlights the association between inflammatory milieu, muscle 
gene expression, muscle atrophy, and muscle function. 
As previously mentioned, we anticipated the fiber-specific cross-sectional area changes due to 
the increased sensitivity to stressors in type II fibers. Translationally, fast twitch fibers control 
balance, strength, and numerous other necessary functions in humans and rodents. It is 
possible that the type II fiber atrophy explains the narrowing of stance in infected mice and 
potentially the increased fall risk in humans due to both weakness and lack of balance. In long-
stay nursing home residents, influenza-like illnesses are associated with a 13% average 
increase in hip fracture hospitalization risk [4]. The corresponding observations during acute 
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illness focused on unsteady gait and dizziness, which also included a greater risk of falls and 
broken bones [4]. The loss of fast twitch fibers in our mice might suggest a potential mechanism 
connecting flu-induced fast twitch fiber loss with fall risk and frailty. Importantly, the decrease in 
mouse fast twitch fiber cross sectional area was prevented by vaccination in both young and 
aged mice. Correspondingly, function was preserved in vaccinated mice as well. We also saw 
increased cellularity in the H&E of unvaccinated mice. In other animal models, cachexia was 
caused by CD8+ T cells during anti-viral responses [52] and some suggest the possibility of 
autoimmune reactivity [53, 54, 55, 56, 57]. Future research is necessary to confirm the identity 
and function of these infiltrating cells during flu infection as it is possible these cells could be a 
potential target for therapeutics.  
In summary, this chapter is the first to identify in a controlled experiment setting flu-induced 
muscle inflammation and atrophy mitigation by vaccination/prior immunity. We demonstrated 
that prior immunity, induced by vaccination, prevents muscle fast twitch fiber atrophy and 
consequently protects muscle functionality. We also determined that vaccine-induced protection 
is not NP antibody mediated (Fig S4) and more research is necessary to determine if protection 
is solely mediated via a T cell dependent mechanism. As disability is one of the major 
complications of flu infection in older adults, the goal of this study was to determine if prior non-
neutralizing immunity could provide protection to skeletal muscle. We determined that 
vaccination indeed could prevent or reduce muscle decrements due to flu infection despite 
reduced vaccine efficacy with aging. Thus, flu vaccination is still an essential part of protecting 
older adults from flu-induced disability. Future research may be able to identify specific 
pathways and therapeutics to fully prevent flu-induced atrophy and potential loss of quality of life 
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Supplemental Figure 1. Experimental plan for the experiments described. The timeline for our 





Supplemental Figure 2. Vaccination to influenza reduced flu-induced functional decrements in 
voluntary locomotor activity, grip strength, and gait kinematics. Young and aged C57BL/6 mice 
were vaccinated with NP/Alum or PBS before being intranasally infected with 500 EID50 of PR8 influenza. 
Mice were acclimated to testing prior to infection and tested for functional performance at designated time 
points. A-G) Gait parameters were assessed utilizing DigiGait, a ventral plane videography treadmill 
system 7 days post infection (n=8-15). G) Spontaneous voluntary activity was assessed via the open field 
test at 8 days post infection (n=10-15/group). I) Grip strength was determined by using a grip strength 
meter at day 8 post infection (n=10-15/group). Data analyzed via two-way ANOVA with Bonferroni post 
hoc corrections comparing to NoVax/NoFlu age-matched controls (*=p<0.05), comparing to NoVax/Flu 





Supplemental Figure 3. Vaccination preserves architecture and nuclear infiltration of young and 
aged skeletal muscle H&E’s. A) The H&E’s are representative for each group at each time point 
analyzed. Scale bars are 100 μm.  B) Blindly scored H&E summaries across each timepoint (n=3-5). C) 
Muscle cross-sectional area via immunofluorescent staining from uninfected (left), unvaccinated/infected 
(middle), and vaccinated/infected (right) 9 DPI young mice. Colors: myosin heavy chain I (red), myosin 
heavy chain IIA (green), myosin heavy chain IIB (yellow), myosin heavy chain IIX (no stain), nuclei (cyan). 
Scale bars are 100 μm. Data analyzed via two-way ANOVA with Bonferroni post hoc corrections 





Supplemental Figure 4. Musculoskeletal protection is not NP-antibody mediated in aged mice. 
Aged C57BL/6 mice were given NP antibody delivered IP or isotype antibody controls before being 
intranasally infected with 500 EID50 of PR8 influenza. A) Treatment and isotype control mice each lost 
equivalent amounts of body mass during flu infection. B) There were no differences in high scoring H&E 
scores between groups (NP antibody left and isotype control right). C) There was no difference in the 
myosin heavy chain type IIB fibers (yellow stained) between groups (NP antibody left and isotype control 
right). D) The adoptive antibodies were not protective against flu-induced gastrocnemius gene expression 
alterations at 9 DPI. All data analyzed via two-way ANOVA with Bonferroni post hoc corrections with 
effect of adoptive antibody treatment (compared to age matched isotype control, p<0.05) indicated by 




RNA sequencing of aged skeletal muscle reveals strong leukocyte 




Influenza (flu) infection leads to loss of independence in older adults. Despite no direct viral 
infection of skeletal muscle, there were alterations in the muscle inflammatory milieu and 
muscle atrophy, with more pronounced and prolonged deficits with aging. To identify potential 
mechanisms of flu-induced muscle atrophy, we employed a multidisciplinary systems-based 
approach to examine the relationship between immune responses, flu-induced inflammation, 
skeletal muscle tissue morphology, muscle function, and full muscle transcriptomics. Our 
integrated approach will test the hypothesis that flu-induced systemic factors lead to muscle 
atrophy, while also generating additional unbiased hypotheses based on transcriptomics and 
statistical modeling to determine the driving mechanisms behind flu-induced muscle atrophy. 
Understanding the mechanisms responsible will then be able to guide preventative and 
therapeutic measures. Furthermore, this study has significant potential to discover high impact 
translational findings that will improve care for flu-infected older adults and help them maintain 






Influenza (flu) is the seventh leading cause of death among older adults in the US with 90% of 
flu-related deaths occurring in late life [1]. Equally compelling from a clinical and public health 
perspective, but less well understood, is the relationship between flu infection and disability. 
Older adults have a greatly increased risk of both progressive and catastrophic disability 
following flu infection [2, 3]. Nevertheless, mechanisms by which flu infection contributes to 
disability remain unknown and unexplored, resulting in missed opportunities for the discovery of 
interventions designed to prolong function and independence in late life. Even in uncomplicated 
cases, flu infections have some degree of muscle involvement with myalgia being a common 
symptom [4]. The studies in this chapter are based on premises from our published work, which 
showed for the first time that flu infection, which by its nature is limited to pulmonary epithelial 
cells [4], results in mobility impairments, muscle inflammation, and increased markers of muscle 
atrophy. Moreover, these effects are more pronounced and prolonged with aging, thus directly 
predisposing older adults to disability following flu infection [5]. However, the pathogenesis for 
this interaction is unknown and little information exists detailing the systematic impact of flu 
infection and how this changes with aging. Here, we aim to define specific mechanism(s) and 
pathways involved in flu-induced muscle atrophy with aging and will lay the groundwork for 
development of preventative measures and therapeutic treatments. Thus, this study has 
significant potential to discover high impact translational findings that will improve care for flu-
infected older adults. 
Our studies have revealed a molecular link between flu infection and disability [5]. Even though 
flu remains a respiratory infection, it exerts distant effects on skeletal muscle in terms of 
functional decline, inflammation and atrophy gene expression; these effects are more severe 
and prolonged with aging. The mechanism behind these outcomes is unclear and warrants 
further investigation. There is no evidence of direct viral infection [5], thus we believe systemic 
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signals from flu infection likely trigger the cascade of muscle-localized inflammation and 
atrophy. Importantly, this supports the notion that other infections that cause systemic 
inflammation to a similar extent will also result in muscle loss with aging. Thus, this chapter will 
delve into mechanisms behind not only flu-induced muscle atrophy, but also other infection and 
inflammation induced myopathies. Indeed, the clinical significance of this thesis transcends flu-
infected older adults and will provide a working framework for other infection-induced disabilities 
and diminished resilience with aging. We hypothesize that exaggerated flu-induced systemic 
inflammation, as well as muscle sensitivity to this inflammation, contributes to increased flu-
induced muscle loss with aging. 
mRNA sequencing (mRNA-seq) is a breakthrough technology that provides quantitative and 
sensitive detection of gene expression levels with a broad dynamic range [6], which was 
demonstrated by Han and colleagues [7, 8]. Indeed, there are many studies which use 
sequencing technologies to investigate skeletal muscle gene changes. A systems biology 
approach revealed a link between systemic cytokines and skeletal muscle energy metabolism in 
a rodent smoking model and human COPD [9]. This is similar to our hypothesis that lung 
infection damage and inflammation is contributing to the myopathy and functional changes. This 
same group, Davidsen and colleagues, reported that several catabolic pathways were 
upregulated and that “hub genes” Cxcl10 and Cntf were at the center of most pathways. In fact, 
elevated levels of pro-inflammatory cytokines have previously been linked to skeletal muscle 
wasting [9, 10]. Additionally, several sources even associate marked reduction in body weight 
with lung damage and attempt to correspond it to changes in skeletal muscle metabolism [11, 
12, 13]. In these studies, the soleus muscle was more directly affected by oxidative stress and 
hypoxia because it is oxidative muscle with high Type I fiber content; lung damage from 
smoking causes less effect in the gastrocnemius muscle which is mixed Type II composition 
that is predominantly glycolytic [9].  
113 
 
Similar studies showed that inflammatory signaling interrupted skeletal muscle development, 
resulting in fibrosis. IFN-γ mediates disruption of energy expenditure-related gene expression by 
repressing Sirtuin 1 (SIRT1) transcription in skeletal muscle cells [14]. SIRT1 activity loss in 
muscle disrupts gene expression, development, and regeneration as well as premature exit of 
cell cycle [15]. Mice also upregulate Fibroblast Growth Factor (FGF-6) after injury to restore 
damaged muscle and without FGF-6, mice develop fibrosis and myotube degeneration [16]. 
Conversely, overexpression of Peroxisome proliferator-activated receptor gamma coactivator 1-
alpha (PGC-1α) in aging muscle enhances a subset of young-like molecular patterns [17]. 
Importantly, myostatin directly regulates skeletal muscle fibrosis [18] as well as Kruppel Like 
Factor 10 (KLF10) gene expression [19]. KLF10 moderates the fibrotic effects of TGF-β 
signaling in chronically damaged regenerating muscle [19]. Collagen, type I, alpha 1 (Col1a1) 
and fibronectin gene expression and protein deposition were increased in KLF10-/- mice, as 
well as increased SMAD2, 3, 4, &7 with downstream effects that increased cardiomyopathy, 
fibrosis, and impaired regeneration [19].  
Adult tissue repair and regeneration require activation of resident stem/progenitor cells that can 
self-renew and generate differentiated progeny. The regenerative capacity of skeletal muscle 
relies on the muscle satellite cells and their interplay with different cell types within the niche 
[20]. We hypothesize that aged mice have greater populations of inflammatory immune cells 
infiltrating and residing in their skeletal muscle post flu infection, which contribute to the delayed 
muscle regeneration and disruption. High-dimensional single-cell sequencing reveals novel 
skeletal muscle resident cell populations of macrophages, neutrophils, B cells (Ptprc, Ms4a1, 
CD19, CD22), T cells (CD4, CD8a, CD3), and CD45+ cells; using single-cell RNA-seq and 
mass cytometry to identify functional populations, characterize their gene signatures, and 
determined key markers [20].  
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We are the first to use a systems-based approach with aging mice and flu infection. It is 
imperative to take a multidisciplinary approach to understand how aging and immunological 
challenge (flu infection) impact skeletal muscle health. By concurrently examining 
immunological parameters, systemic factors (blood cytokines and chemokines), muscle 
function, muscle gene expression, and muscle histology, we can delve more deeply into 
understanding the mechanism(s) of flu-induced muscle atrophy. This is the first unbiased kinetic 
profile of skeletal muscle transcriptome during flu infection. Poly-A RNA-sequencing (RNA-seq) 
has never been performed on skeletal muscle in the context of flu infection, let alone, flu 
infection and aging. Importantly, the mechanism(s) behind the clinical association between flu 
infection and future disability, as well as our findings of flu-induced muscle atrophy are not clear. 
Flu infection, and most likely other infections, represent major stressors that decrease resilience 
and result in increased disability in the older adults. Thus, understanding these mechanisms is 
essential to developing prevention and treatment methods to avert disability and maintain 
independence in old age. 
 
MATERIALS AND METHODS  
Mice. Young (2.5-4-month-old) C57BL/6 male mice were purchased from Jackson Laboratories 
or obtained from the National Institute on Aging. Aged (19-22-month-old) C57BL/6 male mice 
were obtained from the National Institute on Aging rodent colony. All mice were housed in a 
climate controlled environment with 12:12 light:dark cycle and fed standard rodent chow and 
water ad libitum. All mice were cared for in accordance with the recommendations in the Guide 
for the Care and use of Laboratory Animals of the National Institutes of Health. All procedures 
were approved by the UConn Health IACUC. Recumbent mice and mice that lost more than 
30% body weight during the course of influenza infection were considered moribund and 
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euthanized. All mice underwent gross pathological examination at time of sacrifice and animals 
with obvious pathology were excluded from the study. 
Viral infection. Mice were anesthetized with isoflurane and intranasally inoculated with 50 ul of 
500 EID50 of influenza virus A/PR/8/34 (PR8). Mice were weighed daily to monitor infection 
progression. At the indicated time points post-infection, whole lung tissue was homogenized and 
RNA was isolated via TRIzol/chloroform extraction per manufacturer’s protocol (Ambion by Life 
Technologies, Naugatuck, CT and Sigma Aldrich, Natick, MA, respectively). RNA was reverse 
transcribed with iScript cDNA synthesis Kit (Bio-Rad Laboratories, Inc., Hercules, CA) and flu 
viral copies were detected via reverse transcription quantification PCR of flu acid polymerase 
(PA) as previously described [21]. 
Cardiac perfusion protocol. Immediately following CO2 euthanasia, the majority of blood was 
removed via cardiac puncture. The remaining blood was flushed from the animal through 
standard cardiac perfusion. Briefly, a 60 mL syringe containing cold 1xPBS equipped with 
polyethylene tubing was used to perfuse the animal via perfusion pump (WPI SP100I syringe 
pump) at a rate of 47.82 mL/hr. The right atrium was clipped, and a 25g needle attached to the 
polyethylene tubing was inserted at the apex of the base of the heart. Each animal was 
perfused with a minimum of 20 mL 1xPBS until liver began to clear and blood flowing from the 
right atrium was no longer visible. 
Gastrocnemius RNA. To examine gastrocnemius gene expression, mice were fasted with the 
exception of water for 4-6 hours prior to sacrifice in order to minimize potential confounding 
results due to postprandial muscle protein synthesis. The gastrocnemius muscle was dissected 
and placed in RNAlater (Qiagen Inc., Germantown, MD) overnight at 4⁰C. RNAlater was 
removed and the muscle was frozen at -80⁰C until RNA extraction. All RNA isolations were 
performed by the same individual to minimize variability. The muscle was homogenized and 
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RNA was extracted via miRNeasy extraction per manufacturer’s instructions (Qiagen Inc., 
Germantown, MD). RNA quantity and quality were assessed with Nanodrop 2000c (Thermo 
Scientific, Waltham, MA).   
Library preparation and high-throughput sequencing and quantification of gene expression. 
aTotal RNA was checked on a BioAnalyzer (Agilent). mRNA-seq libraries were structed 
according to the standard Illumina TruSeq Stranded mRNA protocol. Paired-end 151-bp 
sequencing was performed on an Illumina HiSeq 2000 (Shelton, CT). Sequencing reads were 
trimmed with trimmomatic [22] to remove the universal Illumina adaptor and uniquely mapped to 
the UCSC mouse reference genome (mm9) and a custom splice junction library in parallel using 
hisat2/2.1.0 [23, 24]. Genes were considered not expressed if they had zero reads in all 
technical and biological replicates. Mapped reads in were counted using HTSeq and then 
differential expression was performed with DESeq2. We continued our analysis with samples 
that contained at least 36 million mapped reads, which excluded samples from analysis for lack 
of genome reads (samples under 9 million reads included SRK017: 74,75,76,77,78,79 and 
SRK018: 67). 
To perform GO analysis. GO analysis was performed via DAVID [25] gene functional 
classification tool. This tool classifies large gene lists into functional related gene groups based 
on representation, which can be interpreted as a cluster of biologically relevant regulatory 
networks or pathways. In our analysis, we considered only GO categories with a false discovery 
rate < 0.05 and pathways with adjusted P <0.05, which we summarize in Supplemental Tables 1 
& 2. Our analysis generated a significant pool of novel, zone-specific genes that were excluded 
from GO and pathway analysis because of missing annotations.  
RT-qPCR. RNA was reverse transcribed via iScript Advanced cDNA synthesis Kit (Bio-Rad 
Laboratories, Inc., Hercules, CA). RT-qPCR was performed using predesigned commercially 
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available primers (Bio-Rad Laboratories, Inc.). Gene expression was calculated via a modified 
Pflaffl method utilizing multiple reference genes (RPS18 and TBP, which showed the least 
variability between conditions and thus suitable reference genes as previously shown (6)) and 
normalized to the uninfected young mice. 
Multiplex Protein Analysis. Bronchiolar lavage fluid (BAL) was collected by flushing lungs with 1 
ml PBS. Supernatant was collected after centrifugation and assayed for cytokine and 
chemokine content. Similarly, blood was collected via cardiac puncture, allowed to clot at room 
temperature, and the resultant serum was assayed for cytokine and chemokine content. 
Gastrocnemius muscle was dissected from each mouse and homogenized in Tissue Protein 
Extraction Reagent (Thermo Scientific, Bedford, MA)) supplemented with 5mM EDTA 
(Invitrogen, Carlsbad, CA) and Protease/Phosphatase Inhibitor Cocktail (Thermo Scientific)). 
Debris was removed via centrifugation and total protein content was determined using a 
Pierce™ BCA Protein Assay Kit (Thermo Scientific).  
Voluntary locomotor activity. Spontaneous voluntary locomotor activity was measured via open 
field test at time points indicated. All tests were performed between 7-9am to control for diurnal 
variations. Following acclimation to the dim-lit testing room (at least 1 hour), mice were placed in 
the center of the photobeam activity system-open field (PAS-OF, 16”x16”x15” acrylic animal 
enclosure, San Diego Instruments, San Diego, CA) and their activity was recorded for 20 
minutes. The first 5 minutes was excluded as this is generally considered to be exploratory 
behavior rather than general voluntary locomotor activity. The number of beam breaks per 
minute during the last 15 minutes was then used to assess voluntary locomotor activity. 
Grip strength. Grip strength was determined by using a grip strength meter BIOSEB (In Vivo 
Research Instruments, Pinellas Park, FL). Briefly, mice were permitted to grab onto a T-shaped-
bar and pulled horizontally by the tail until they released their grip. The force (grams) read by 
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the force meter at the release of the mouse’s grasp was averaged by their mass (grams) on that 
day and compared to their pre-infection results. The same researcher performed all testing to 
minimize variability.  
Gait analysis. Gait analysis was performed using the DigiGait instrument (Mouse Specifics, Inc. 
Quincy, MA) and software (DigiGait Imager 4.0.0 and DigiGait Analysis 11.5, Mouse Specifics, 
Inc). The DigiGait instrument consists of a clear treadmill with a high-speed camera mounted 
underneath that collects images at 147 frames per second for high resolution of postural 
temporal gait parameters. Mice run within a 2-inch-wide acrylic running chamber at set speeds. 
The ventral plane videos are analyzed with the DigiGait software which identifies portions of the 
paw that are in contact with the treadmill belt to produce both postural and kinematic gait 
parameters. Mice were introduced to the DigiGait system at a low speed (10cm/sec) briefly (30 
seconds) prior to the initial testing. Mice were allowed to acclimate to the dim-lit room for 1 hour 
prior to each testing period and all tests were performed between 8-10 am. Mice ran at the 
testing speed (16cm/sec, as previously optimized (6)) until approximately 5 seconds of 
consecutive walking was recorded and this video segment was analyzed via DigiGait software.  
Histology. The gastrocnemius muscle was carefully dissected and blotted on a Kim Wipe before 
being placed in a cryomold, embedded in Optimal Cutting Temperature (OCT ThermoScientific 
Inc., Waltham, MA) and frozen in liquid nitrogen cooled isopentane. Samples were stored in the 
freezer at -80° Celsius until sectioned. Ten-micron thick muscle cross sections were mounted 
on charged slides (Superfrost Plus Glass Slides, ThermoScientific Inc., Waltham, MA) for 
histological analyses. Serial sectioned (10um) muscle was fixed in ice-cold acetone for 3 
minutes and stained with antibodies against laminin, CD45, CD3, CD31, and Lyve1 (Table 1 
below). Sections were blocked for 30 minutes with 2% goat serum, stained over night at 4oC in a 
humidified chamber with primary antibody cocktail, washed in PBS and then stained for 2 hours 
at room temperature with secondary antibodies. Slides were mounted with Immu-Mount 
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(Thermo Scientific), cover slipped and sealed. Images were acquired using the Zeiss 880 laser 
scanning microscope (Carl Zeiss; air objective 20× Plan-Apochromat with NA 0.5). For analysis, 
four z-stack (4-0.5um steps) images per mouse were acquired of the skeletal muscle cross-
section with the 20x objective. Volume and disconnection of laminin and vessels were quantified 
using the isosurface tool in Imaris 8.1 software (BRITPLANE). Laminin was used to detect the 
basement membrane of the skeletal muscle. CD45 and CD3 were used to detect leukocytes 
and T lymphocytes, respectively; while CD31 and Lyve1 were used to detect blood vessels and 
lymphatic vessels, respectively.  Images were acquired on a Zeiss LSM880 confocal 
microscope and analyzed via Imaris software. Intramuscular leukocytes were identified by 
CD45+Lyve1-CD31- within laminin borders. Intramuscular T cells were identified by CD3+ 
CD45+ Lyve1- CD31- within laminin borders. 
Table 1. Antibodies used for phenotyping infiltrating cells in skeletal muscle by 
immunofluorescence. 
Antibody Fluorochrome Clone Manufacturer 
Anti-Laminin, Polyclonal 
Laminin (primary) 
Unconjugated LAMA1 Novus Biologicals ™ 
Donkey anti-rabbit IgG 
Laminin (secondary) 
BV510 Poly4064 Biolegend 
CD3 AF647 17A2 Biolegend 
CD45 PE 30-F11 Biolegend 
Lyve1 AlexaFluor488 ALY7 eBioscience 
CD31 BV421 MEC13.3 BD 
 
Statistical analysis. All data analyzed via two-way (DPI x age) ANOVA with Bonferroni post hoc 
corrections. Significant differences comparing to baseline (0 DPI) age-matched controls 
(*=p<0.05), and comparing between groups/ages within a condition (brackets=p<0.05). RNA-
seq data was analyzed as noted above. Several contrast comparisons were made from the 
DESeq2 results at an adjust P-value < 0.05: contrasting Young 0 DPI to every other Young DPI, 
Contrasting Aged 0 DPI to every other Aged DPI, and Contrasting Young and Aged at the same 
DPI. Heatmaps were created based off genes with log2FoldChange > 2 or log2FoldChange < -2 
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with an adjusted P-value < 1e-2. The hierarchal clustering was performed with Spearman 
method for gene expression association analysis. Volcano plots were given a cutoff of P-value = 
5e-2 and 2 log2 fold change. Gene ontology pathway analysis with DAVID used q-value cutoff = 
5e-2 and required genes to have at least a log2 fold change with and adjusted p-value 1e-2. 
 
RESULTS 
Aged mice have increased weight loss and increased flu PA copies in the lung during infection, 
simultaneously with prolonged functional deficit. This data, from a new cohort of mice, matches 
our previously shown data in chapter 2 [5] and chapter 3 [unpublished Keilich et al]. Aged mice 
have greater and prolonged weight loss during flu infection when compared to their young 
counterparts (Fig1A) and aged mice plateau at 10% loss from their starting body weight. Aged 
mice also display delayed viral clearance compared to young counterparts on days 9 and 11 
post infection (Fig1B). Functionally, aged mice have greater deficits at 11 days post infection 
(DPI) than their young counterparts when measuring grip strength (Fig1C). Open field testing, 
which measures the voluntary motion of mice, demonstrated that young mice were more mobile 
than aged mice at pre-infection baseline trials and across all other testing time points except 7 
DPI where they performed equally (Fig1D). Due to the fact that young and aged mice had 
different starting points in DigiGait analysis parameters, we decided to draw comparisons to 
each mouse’s “pre-infection” test so that each mouse is compared to its own baseline results 2 
days prior to infection denoted -2 DPI (Fig1E-I). Aged mice had significantly decreased stance 
width at 5 of the 8 time points (Fig1E) and did not return to pre-infection stance, whereas their 
young counterparts were insignificantly different from their pre-infection stance width after 15 
days post infection. The time in “stance” with the paw on the ground was increased and 
prolonged in aged mice, but not in young mice (Fig1F). Similar trends were seen in the aged 
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mouse time in “swing” with the paw in the air and time in “stride” (Fig1G-H). Young and aged 
mice followed similar trends for time in the “propel” stage of stepping (Fig1I). These data are 
further verified by forelimb data (data not shown).  
 
Figure 1. Aged mice have increased weight loss and increased flu PA copies in the lung during 
infection, simultaneously with prolonged functional deficit. Young and aged C57BL/6 mice were 
intranasally infected with 500 EID50 of PR8 influenza. A) The percent body mass loss graphed over the 
course of the experiment. B) Influenza acid polymerase (PA) copy number determined by RTqPCR of 
mouse lungs at given time points. C) Grip strength was determined by using a grip strength meter. D) 
Spontaneous voluntary activity was assessed via the open field test. E-I) Gait parameters were assessed 
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utilizing DigiGait. Data analyzed via two-way ANOVA with Bonferroni post hoc corrections comparing 
young and aged mice (brackets=p<0.05) and comparing to age-matched pre-infection (*=p<0.05). 
Inflammation is elevated and prolonged with aging in BAL and serum. Bronchoalveolar lavage 
(BAL) was collected from mice at the time of sacrifice. Granulocyte-colony stimulating factor 
(GCSF) is a glycoprotein that simulates the bone marrow to produce granulocytes (primarily 
neutrophils) and stem cells and release them into the blood stream. Interleukin 1 alpha (IL-1α is 
responsible for production of inflammation as well as the promotion of fever and/or sepsis. Aged 
mice had significantly more GCSF and IL-1α in the BAL compared to young mice on 5, 7, and 9 
DPI (Fig 2A & 2D). Granulocyte-macrophage colony-stimulating factor (GMCSF) is a monomeric 
glycoprotein secreted by macrophages, T cells, mast cells, natural killer cells, endothelial cells 
and fibroblasts that functions to stimulate/produce neutrophils, eosinophils, and basophils. Aged 
mice had significantly more GMCSF than young mice in the BAL on 7, 9, and 11 DPI (Fig 2B). 
Interferon gamma (IFN-γ) is a cytokine that is critical for innate and adaptive immunity against 
viral and some bacterial infections. IFN-γ is capable of activating the JAK-STAT pathway on 
cells and is an important activator of macrophages and inducer of class II major 
histocompatibility complex (MHC) molecule expression. IFN-γ was only different from in aged 
mice 7 DPI (Fig 2C). In BAL and serum, interleukin 6 (IL-6) promptly and transiently is produced 
to contribute to host defense through stimulation of acute phage responses, hematopoiesis, and 
immune reactions. IL-6 is very pleiotropic and has different effects in different environments. 
CXCL10 is also known as interferon gamma-induced protein 10 which is considered to be a 
proinflammatory chemokine for inflammatory cell types carrying the CXCR5 receptor. IL-6 and 
CXCL10 were both significantly upregulated in aged mice compare to young counterparts on 7 
and 9 DPI (Fig 2E & 2F). Tumor necrosis factor alpha (TNF-α) is a cell signaling protein involved 
in systemic inflammation and is one of the cytokines that make up the acute phase reaction. 
The cytokine that had the greatest age difference was TNF-α, which reported higher levels in 
aged mice on 5, 7, 9, and 15 DPI when compared to young (Fig 2G). Interestingly, serum levels 
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of GCSF had opposite trends in young and aged mice (Fig 2H), where young mice were 
significantly decreased on days 9 and 11 when compared to young 0 DPI. Aged mice were only 
significantly increased compared to young 9 DPI (Fig 2H). Serum GMCSF was higher in aged 
mice compared to young 9, 15, and 20 DPI (Fig 2I). Serum IFN-γ and IL-1α did not have age 
differences at measured time points. Serum IL-6 and TNF-α had age differences on 9 DPI but 
TNF-α did not have any increase in young mice (Fig 2L and 2N). Serum CXCL10 peaked in 
both young and aged mice 7 DPI, but was higher in young mice 5 DPI and higher aged mice 9 
and 11 DPI (Fig 2M). Overall, young mice resolved inflammation more quickly than aged 
cohorts and aged mice had increased levels of inflammatory cytokines compared to young 
mice. 
 
Figure 2. Inflammation is elevated and prolonged with aging in BAL and serum. Young and aged 
C57BL/6 mice were intranasally infected with 500 EID50 of PR8 influenza. A-G) Bronchoalveolar Lavage 
(BAL) was collected from mice at time of sacrifice as described in methods. The BAL was then analyzed 
via Millipore chemokine/cytokine Multiplex 25-plex for the analytes. H-N) Serum was collected from mice 
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at the time of sacrifice as described in methods. The serum was later analyzed via Millipore 
chemokine/cytokine Multiplex 25-plex for the analytes listed. Data analyzed via two-way ANOVA with 
Bonferroni post hoc corrections comparing young and aged mice (brackets=p<0.05), comparing to age-
matched 0 DPI (*=p<0.05). 
Determination of age and DPI specific differences in gene expression using RNA sequencing. 
The RNA extraction and library preparation were performed as stated in the methods section 
with samples from two rounds of the same experiment run together. Mapped sample reads were 
analyzed with DESeq2 with comparisons between age groups and days post infection. The data 
then underwent principal component analysis (PCA), which is a statistical procedure that uses 
orthogonal transformation to convert a set of observations of possibly correlated into a set of 
values of linearly uncorrelated variables called principal components. These principal 
components are plotted in PCA plot (Fig 3A), which shows that the overall gene expression 
profiles of the samples cluster primarily by infection (DPI), and then by age. This demonstrates 
that comparisons can be made between groups because the replicates of each group are 
similar to each other and distinct from other groups. Similarly, we observed similar gene 
changes in groups from different batches (Fig 3B), where mice had the same gene trends at the 
same ages and DPI. Indeed, when clustered in smaller groups (comparing ages at the same 
DPI or comparing DPI within age groups), mice are blindly clustered with other samples in their 
infection, age, and DPI groups (Fig 3C and data not shown). Overall, these are excellent 
indications that skeletal muscle global gene expression is changing with respect to time point 







Figure 3. Determination of age and DPI specific differences in global gene expression. We 
performed pair-end 151-bp polyA-selected sequencing was performed using an Illumina HiSeq 2000. A) 
Principal Component Analysis plot of all samples. B) Heatmap of all samples showing breakdown of 
meta-data groups and general whole sample gene changes. C) Clustered histogram comparing young 
(SRK017.01-SRK017.05 & and SRK018.01-SRK018.05) and aged samples (SRK017.06-SRK017.10 & 
and SRK018.06-SRK018.10) at 0 DPI. 
Young and aged mice undergo different kinetics for inflammation and gene expression changes. 
Young and aged mice have significantly different gene expression at 0 DPI (Fig 3C and Fig 4A), 
with extra cellular matrix (ECM) genes such as Actc1 and Col1a1 downregulated in aged mice. 
At 9 DPI, aged mice have increased expression of chemotaxis genes compared to young mice 
with upregulated CXCL13, CXCL2, and CCL8 to name a few (Fig 4B). Additionally, aged mice 
have TGF-β superfamily genes, such as GDF5, upregulated in conjunction with continued 
downregulation of ECM genes (Fig 4B). These expression patterns continue on 11 DPI (Fig 4C) 
and as far out as 20 DPI (Fig 4C). Interestingly, we observed that aged mice had increased 
expression of inflammatory cytokines such as IL-6, IL-1β, and IFN-γ, as well as pro-
inflammatory chemotaxis signals such as CXCL10, on 20 DPI (Fig 4D). Venn diagrams 
comparing gene expression of acute infection timepoints (Fig 4E and 4F) and resolving infection 
timepoints (Fig 4G and Fig 4H) displays that young and aged mice have similar overall changes 
in gene expression due to infection, but young mice see these changes at earlier time points 
than aged mice; and aged mice see continued expression long after these changes resolve in 
the young. All of the significant genes (adjusted p-value < 0.01) with significant fold changes 
(greater than +/- 1 log2 fold) were compiled and used for pathway analyses. Identifying 
significant pathways will highlight processes and genes that are “centric” or considered “hub 
genes” that are connected to multiple pathways in flu-induced muscle changes. Similar genes 
were upregulated in young and aged mice with infection, but the changes in aged mice occurred 








Figure 4. Young and aged mice undergo different kinetics for inflammation and gene expression 
changes. A-D) Volcano plots comparing aged to young mouse expression at the given timepoint. We 
applied a cutoff for significance at p = 0.05 and twofold change in expression to determine differentially 
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expressed genes. E-H) Venn diagrams shows the acute (E-F) and resolving (G-H) infection in young 
(E&G) and aged (F&H) mice after pairwise comparison to age-matched 0 DPI. We applied an adjusted-P-
value < 0.05 and twofold change in expression to determine differentially expressed genes.  
Pathway analysis of aged skeletal muscle RNA-Sequencing reveals strong leukocyte activity 
during pulmonary influenza infection. Pathway analysis of significantly upregulated and 
downregulated genes using DAVID gene ontology [25] revealed the differences in aged 
pathway expression compared to young pathway expression at given timepoints (Fig5). 
Graphed in Figure 5 are the top 20 significant pathways calculated, the full list of pathways and 
genes involved is in Supplemental Table 1 and Supplemental Table 2. Without infection, young 
mice are more adept at ECM organization and skeletal muscle development, which is shown in 
the pathway downregulation of aged mice at 0 DPI compared to young mice (Fig 5A). 
Interestingly, only aged mice displayed T cell aggregation, T cell activation, and other 
upregulated positive expression for leukocytes and lymphocytes (Fig 5B). These immune cell 
mediating pathways were most significant in the aged mice and continued across timepoints 
until about 30 DPI (Supplemental Table 1). Aged muscle underwent greater stress pathway 
upregulation with genes that triggered oxidative stress, apoptosis, and ubiquitin catabolic 
pathway results (Fig 5C). In addition, downregulation of pathways involved in sarcolemma, ECM 
organization, and regeneration were observed in aged mice 9 DPI (Fig 5C). Many of these 
catabolic upregulated pathways and downregulated regeneration pathways persisted in aged 
compared to young muscle out to 20 DPI (Fig 5D and Fig 5E). We observed downregulated 
pathways for axonogenesis, neuron development, and neuromuscular repair pathways 11 DPI 
that were unique to aged muscle (Fig 5D). Indeed, this GO pathway analysis highlights the aged 
muscle’s lack of regenerative capacity, degradation, and emphasis on prolonged immune cell 







Figure 5. Pathway analysis of aged skeletal muscle RNA-Sequencing reveals strong 
leukocyte activity during pulmonary influenza infection. A-E) Dot plots of gene ontology 
pathway analysis via DAVID. We applied an adjusted-P-value of 1e-2 and twofold change in 
expression to determine differentially expressed genes for pathway analysis. 
Increased leukocyte and T cell infiltration in the skeletal muscle. Our GO pathway results 
highlighted several chemokine pathways as well as leukocyte and T cell markers which were 
specific to aged but not young mice expression. Upon further investigation, we probed muscle 
sections for CD45+ cells, which were Lyve-1- to ensure that they were not in the lymph vessels 
and CD31- to ensure that they were not in the blood vessels (Fig 6A-H). We found that aged 
muscle had the most significant increase in CD45+ cells on 15 DPI (Fig 6A). Following a similar 
pattern, CD3+ cells were on seen to increase in aged muscle 11 DPI and 15 DPI when 
compared to young mice (respectively 11 DPI and 15DPI) and aged 0 DPI. Thus, gene 
expression changes observed in the pathway analysis correspond to observed cell populations 
in skeletal muscle, suggesting that flu leads to pro-inflammatory cell infiltration in aged skeletal 






Figure 6. Increased leukocyte and T cell infiltration in the skeletal muscle. Young and aged C57BL/6 
mice were intranasally infected with 500 EID50 of PR8 influenza and sacrificed at day post infection (DPI) 
indicated. Serial sectioned (10um) muscle was stained with antibodies against laminin, CD45, CD3, 
CD31, and Lyve1. Laminin was used to detect the basement membrane of the skeletal muscle. CD45 and 
CD3 were used to detect leukocytes and T lymphocytes, respectively; while CD31 and Lyve1 were used 
to detect blood vessels and lymphatic vessels, respectively.  Images were acquired on Zeiss LSM880 
confocal microscope and analyzed via Imaris software. A) Quantification of intramuscular leukocytes were 
identified by CD45+Lyve1-CD31- within laminin borders. B) Quantification of intramuscular T cells were 
identified by CD3+ CD45+ Lyve1- CD31- within laminin borders. C-H) Representative images of young 
and aged muscle with CD3 (red), CD45 (yellow), Lyve-1 (green), CD31 (blue), and Laminin (purple). Data 
analyzed via two-way ANOVA with Bonferroni post hoc corrections comparing young and aged mice 
(brackets=p<0.05), comparing to age-matched 0 DPI (*=p<0.05). 
 
DISCUSSION 
This project is a multidisciplinary effort to determine the mechanisms at the interface of aging, 
flu infection, and muscle health. Our novel finding that pulmonary flu infection influences specific 
changes in skeletal muscle gene expression and function has culminated in this study [5]. Aging 
increases the negative impact of flu infection on skeletal muscle health [26]. Another 
observation is that flu-induced changes in skeletal muscle expression of inflammatory and 
atrophy genes were increased to a greater amplitude and duration in aged animals. Flu infection 
also decreased expression of positive regulators of muscle mass and myogenesis to a greater 
degree in aged mice. Additionally, aged mice had prolonged mobility and functional decrements. 
Flu-related disabilities in the older adults are an extremely urgent clinical problem, especially 
with an ever-increasing older adult population. Understanding the molecular mechanisms that 
link flu infection and disabilities could lead to novel therapeutic discoveries to decrease post-
infection disability with aging.  
Flu infection instigated inflammation in the BAL and serum of both young and aged mice that 
was more pronounced and prolonged with aging. Prior to autophagy and ubiquitin pathway 
activation, the first pathways to change expression in the skeletal muscle are upstream of the 
NF-κB pathway and inflammasome pathways. Both of these trigger inflammatory responses in 
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skeletal muscle in response to systemic inflammatory factors. In fact, our sequencing showed 
guanylate binding protein 5 (GBP5), activator of NLRP3 inflammasome assembly, was triggered 
through IFN-γ signaling. Circulation of IFN-γ, TNF-α, and IL-6 in the blood during peak infection 
precedes changes in skeletal muscle gene expression. Skeletal muscle is highly vascularized 
and contains a variety of mononuclear cells, including those in peripheral blood, as well as 
endothelial cells, fibroblasts, and myogenic satellite cells [27]. Therefore, cytokines in the blood 
have been shown to induce metabolic changes in skeletal muscle during lung trauma [9, 11, 12, 
13]. Some of our observed cytokine influxes in the serum during flu-infection – IFN-γ, IL-1α, IL-
6, TNF-α – are known to cause muscle atrophy and block muscle maturation/differentiation [10]. 
These cytokines act as the catalyst of change for skeletal muscle and we hypothesize that the 
changes we observe are triggered by mechanisms downstream of their signaling.  
More specifically, similar studies showed that inflammatory signaling interrupted skeletal muscle 
development, resulting in fibrosis. Simultaneous IFN-γ and TNF expression lead to increases in 
pro-inflammatory chemokines such as CCL5, CXCL9 and CXCL10. IFN-γ also mediates 
disruption of energy expenditure-related gene expression by repressing Sirtuin 1 (SIRT1) 
transcription in skeletal muscle cells [14]. SIRT1 activity loss in muscles disrupts gene 
expression, development, and regeneration as well as premature exit of cell cycle [15]. Our 
sequencing revealed this decrease in SIRT1 in our aged cohorts compared to young at the 
same timepoints suggesting the impact of IFN-γ was more impactful in aged skeletal muscle. 
Mice upregulate FGF-6 after injury to restore damaged muscle; but without FGF-6, mice 
develop fibrosis and myotube degeneration [16]. Compared to young mice, aged mice had 
downregulated expression of FGF-6 and similar downregulation myogenic signals. Importantly, 
myostatin directly regulates skeletal muscle fibrosis [18] as well as KLF10 gene expression [19]. 
KLF10 acts to inhibit TGF-β and its suppression increases the risk of fibrosis in aged muscle. 
Col1a1 and fibronectin gene expression and protein deposition were increased in KLF10-/- 
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mice, as well as increased SMAD2, 3, 4, &7 with downstream effects [19]. KLF10 moderates the 
fibrotic effects of TGF-β signaling in chronically damaged regenerating muscle [19]. The aged 
mice in our study follow similar trends during KLF10 downregulation, displaying increased 
SMAD gene expression and increased fibronectin gene expression. With these changes in 
expression, we see fibrosis staining in aged mouse skeletal muscle (chapter 3). Aged mice start 
to upregulate T cell chemotaxis and activation GO pathways as early as 7 DPI. One of the 
genes in these pathways is T cell specific GTPase 1 (Tgtp1), which is induced by IFN-γ. 
Moreover, the downstream effects of IFN-γ have multiple implications on many of these genes 
and their pathways. 
Additionally, the other factors in the serum that we report on – GCSF, GMCSF, CXCL10 – all 
have the capacity to activate and stimulate white blood cell proliferation and trafficking. Taken 
together, this inflammatory milieu has been shown to not only directly impact skeletal muscle 
homeostasis, but also potential immune cells circulating in the blood that traffic into the muscle 
following muscle chemotaxis signaling (Fig 5 & 6). Here, we aimed to determine the mechanism 
of flu-induced muscle atrophy with aging. We hypothesized that exaggerated flu-induced 
systemic inflammation, as well as increased muscle sensitivity to this inflammation contributes 
to immune cell infiltration into the skeletal muscle and increased flu-induced muscle atrophy with 
aging. We found upregulation of chemokines such as CXCL10, which promotes immune cell 
infiltration, in young and aged skeletal muscle tissue with dramatically higher and prolonged 
expression only in the aged muscle. Correspondingly, immunohistochemistry of murine 
gastrocnemius muscle revealed higher numbers of leukocytes during flu infection in young and 
aged mice with a prolonged elevation in the aged mice. Interestingly, an influx of T lymphocytes 
only occurred in aged muscle later in infection (Fig 6A and Fig 6B). It is possible that infiltrating 
T cells are causing undue harm to the aged muscle potentially hindering muscle regeneration 
and functional recovery.  
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Indeed, it is likely T cell infiltration contributes to increased muscle damage and atrophy during 
flu infection with aging as well as other inflammatory leukocytes observed in our GO pathway 
results (Fig 5 and supplemental Table 1). Further analyses will determine the phenotype of 
these T cells and other leukocytes via flow cytometry or single cell RNA-Seq, as well as 
determining the etiology of the CXCL10/CXCR3 axis within skeletal muscle during flu. 
Understanding the molecular mechanisms that link flu infection and physical disabilities could 
lead to novel therapeutic discoveries to decrease post-infection disability with aging. In fact, 
other research into resident cell types of skeletal muscle has illuminated the existence of 
immune populations but chose to focus on other aspects of new progenitor cell populations [20]. 
Additionally, an alternate approach to examine these cells is to digest the muscle and perform 
flow cytometry as previously described [28, 29]. These leukocytes are necessary for skeletal 
muscle regeneration and signaling muscle precursor cell activation and differentiation, however, 
their prolonged presence and inflammation points to more fibrosis pathways.  
In chapter 3, the infiltrating T cells have been identified in our microscopy by CD3+ cells and 
have not been further identified as CD4+ or CD8+ T cells. These cells would be easily 
identifiable via flow cytometry. The markers for CD4 and CD8 would quickly denote T cell 
subset, but activity could also be determined by expression of B cell leukemia/lymphoma 3 
(BCL3), T cell specific GTPase 1 (Tgtp1), IL4rα, IL2rγ, V-set and immunoglobulin domain 
containing 4 (Vsig4) (all of which were observed in GO pathways for T cells in our experiment). 
Additionally, we can use granzyme staining to look for cytotoxic T cells, CD44hi cells as those 
being antigen experienced, CD69 in T cells following activation, downregulation of CD62L in 
activated T cells, and CD25 for regulatory T cells.  Indeed, the literature supports that both 
CD4+ and CD8+ T cells are present in the skeletal muscle for various reasons. Diane Mathis’ 
group shows that CD8+ T cells have the potential aid in regeneration or cause inflammation to 
the environment. Similarly, subsets of CD4+ T cells secreting IFN-γ can cause harm to muscle 
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tissue repair, but CD4+ Tregs can limit IFN-γ production and quell inflammatory macrophages 
[30, 31, 32]. Similarly, single cell RNA-seq has shown the presence of both CD4+ and CD8+ T 
cells in skeletal muscle during homeostasis, but did not go into further detail [20].  
To determine the role of infiltration and T cells during infection, we hope to use a skeletal 
muscle specific inducible knockout of CXCL10 mouse from Jackson Laboratory (B6.129S4-
Cxcl10tm1Adl/J), which has impaired proliferation and IFN-gamma secretion following antigenic 
challenge. This mouse has reduced contact hypersensitivity compared to wildtype mice and are 
considered useful in studies of Th1-type inflammatory disease, chemokine biology, and T cell 
priming, proliferation, and trafficking. Through preventing T cell admission to the skeletal 
muscle, we would be able to tease out the role and impact of their presence in the muscle. If the 
T cells infiltrating the skeletal muscle were inflammatory, I expect to see improvement in the 
aged muscle histology, function, and decreases in inflammation. If these T cells were aiding in 
regeneration and dampening inflammation, then I would expect to see worsened pathology. 
However, our results suggest that these cells are pro-inflammatory and are responding to pro-
inflammatory chemokines as well as potentially responsible for producing the pro-inflammatory 
cytokines (TNF, IFN-γ, IL-1β, and excessive IL-6) that remain elevated in aged mice past 20 
DPI. Moreover, this conditional knockout model would determine if the difference in aged 
skeletal muscle recover is due to the infiltrating inflammatory cells. Through limiting the 
chemotaxis of inflammatory cells, which do not disappear in aging as they do in young mice, we 
hypothesize that aged skeletal muscle would not have prolonged inflammation or lasting 
disability.  
Interestingly, there is a link between influenza and central and peripheral nervous system 
complications, which we highlight in chapter one of this thesis. Several events occur 
simultaneously in only aged cohorts of mice, which point to a new hypothesis that autoimmune 
reactive T cells are causing damage to neuromuscular junctions and demyelinating aged 
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skeletal muscle. While we do not directly examine aspects of nervous system damage, pain, or 
sensory reflex in our mice, several other key elements are all present. Our data shows mRNA 
and protein levels of CXCL10 to be upregulated in only aged mice, just before increased T cell 
presence via immunofluorescence. This increased cell traffic was observed at 9 and 11 DPI, 
which coincides with disrupted tissue architecture in H&E staining, fibrosis/collagen staining via 
Masson’s Trichrome, and decreased cross-sectional area of fast-twitch fibers (MyHC IIB 
atrophy). Further, our Gene Ontology (GO) pathway analysis showed that aged cohorts had 
downregulated axon development, downregulated axonogenesis, downregulated regulation of 
axonogenesis, increased regulation of apoptotic signaling pathways, extrinsic apoptotic 
signaling pathways, and more suggesting negative impacts to nervous system via external 
signals. In addition, aged cohorts exhibited GO pathway upregulation for T cell activation and 
leukocyte migration as early as 7 DPI, which lasted through 20 DPI with notable increases in 
inflammatory cytokines/chemokines in the muscle at 20 DPI. To confirm that this was not an 
affect of direct viral interaction, we performed flu RT-qPCR on skeletal muscle and found no 
evidence flu presence. Taken together with the prolonged loss of function in aged cohorts, 
which has been shown in the literature to be signs of denervation. Aged mice have significantly 
decreased abilities in grip strength and open field testing from 7-19 DPI (Fig 1). We also 
observed lasting alterations in gait kinematics of aged mice. We originally contributed these 
observations to loss of fast twitch fibers (chapter 3), but now have to consider the possibility that 
there is also denervation present. Based on this data, our hypothesis is that aged mice have 
upregulation of chemokines that call in autoreactive T cells, which causes the observed 
changes in gene expression and function because of the damage/disruption to neuromuscular 
junction and axons in the skeletal muscle tissue. More specifically, we observed inhibition of 
acetylcholinesterase (AChE) in aged muscle, which leads to accumulation of acetylcholine (Ach) 
in the synaptic cleft and results in impeded neurotransmission. Impeded neurotransmission 
such as this is observed in diseases such as myasthenia gravis, where the end plate potential 
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(EPP) fails to effectively activate the muscle fiber due to an autoimmune reaction against 
acetylcholine receptors, resulting in muscle weakness and fatigue [33, 34]. Impeded 
neurotransmission also causes destabilization of coordination and reduced muscle strength 
[35]. Normally, AchE terminates signal transduction at the neuromuscular junction by rapid 
hydrolysis of the Ach released into the synaptic cleft. Similarly, synaptotagmin IX (SYT9) is 
involved in Ca2+ dependent exocytosis of secretory vesicles through Ca2+ and phospholipid 
binding to the C2 domain and is also disrupted in aged muscle. Evidence of demyelination and 
autoimmunity comes from pathways associated with apolipoprotein D (ApoD), a hub gene in our 
analysis associated with neurological nerve injury especially related to the myelin sheath. 
According to the literature, muscle fibers continue to undergo atrophy after denervation, with 
collagen deposits forming in the endomysium and perimysium [36]. In our own studies, the gene 
expression we observed points to denervation occurring in aged cohorts simultaneously with 
collagen deposits described in our H&E and trichrome staining (chapter 3). As stated above, 
further studies are necessary to verify this hypothesis and these juxtaposed observations. 
However, the preliminary observations which point to this hypothesis cannot be ignored and if 
true have huge clinical ramifications.  
Inflammaging is detrimental to many facets of the immune system and full body homeostasis. 
Using selective pharmaceutical/biochemical inhibitors to disrupt exorbitant and prolonged 
inflammation would theoretically restore/rejuvenate normal systems. As long as essential 
signaling pathways to influenza clearance are not disrupted, infection clearance will ideally 
continue as it normally would without blockers. For this reason, IL-6 cannot be targeted because 
it is essential to many systems including muscle homeostasis, stem cell activation, immune cell 
signaling, and most importantly in these circumstances, viral clearance [38]. Cyclooxygenase 
(COX)-1 and COX-2 are involved in pathways that are important in modulating immune 
responses, including body weight and temperature changes. COX-1 deficient mice have 
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enhanced inflammation and increased mortality with profound hypothermia and greater weight 
loss [38, 39]. COX-2 is associated with inflammatory responses and has increased expression 
with age-related and flu-induced manners; COX-2 specific inhibition attenuates inflammation 
and viral titers [38-47]. COX-2 upregulation leads to proinflammatory cytokines in the BAL and 
enhanced inflammation systemically; it also drives mice into hypothermic states and to lose 
weight with infection. Inhibiting COX-2 has proven to reduce mortality from infection, maintain 
weight with infection, and blunt inflammatory cytokine responses including G-CSF and TNFα 
[38-42]. Selective COX-2 inhibition with celecoxib reverses wasting and associated cachexia 
[45-47] and has even been given to geriatric hospital patients with acute inflammation from 
infectious disease to reduce muscle fatigue and improve mobility [45]. It is believed that COX-2 
inhibition does not significantly modulate disease severity [39]. COX-2 along with TNFα and 
other proinflammatory cytokines were hyperinduced in epithelial cells and infected macrophages 
during flu infection [42]. In fact, COX-2 and TNFα have been shown to upregulate each other 
when once one is present. Inflammatory molecules, such as TNFα, increase in serum 
concentration with aging and activate NF-κB in differentiated skeletal muscle myotubes to 
induce protein degradation [48, 49]. Evidence supports TNFα receptor-mediated apoptotic 
events increase with age, especially in type II fiber-containing muscles [48]. By age 80 an 
estimated 30-40% of skeletal muscle fibers are lost [48]. TNFα blocking antibodies have been 
used in geriatric patients with rheumatoid arthritis and other inflammatory diseases to reduce 
inflammation and reduce muscle atrophy. TNFα exposure up-regulates Atrogin1/MuRF1 mRNA 
to mediate atrophy in myotubes in vitro within 2 hours of exposure [50, 51]. TNFα acts directly to 
stimulate loss of muscle protein, binding to the surface receptors to increase ROS activity with 
skeletal muscle fibers and upregulate NF-κB [49-52]. It is a catabolic cytokine which increases 
with age, especially in fast twitch fibers and in the serum [48]. TNFα-activated pathway 
negatively regulates satellite cells number and expression/differentiation in regenerating 
muscles [51]. Neutralizing antibodies against TNFα such as infliximab have been successful in 
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reducing systemic levels of TNFα and promote muscle regeneration [53, 54]. Infliximab is a 
monoclonal anti-TNFα antibody that binds specifically to TNFα with high affinity binding; it is 
chimeric composed of both human and mouse proteins and given as an intravenous infusion to 
humans [53]. It is our goal to halt the myopathy and damage done to muscle by inhibiting these 
known pathways for muscle degradation during influenza infection. Since we are not able to 
block major cytokines and inflammatory pathways without also impairing the host immune 
response, we chose COX-2 and TNFα to inhibit as they do not have huge roles in clearance of 
influenza virus. We hypothesize that by decreasing flu-inflammation we can improve the 
molecular and functional skeletal muscle pathways normally disrupted in aging/flu-infection. 
With inflammaging, it is more likely for the elderly to scar or develop fibrosis in tissues, rather 
than regenerate lost muscle; therefore, it is imperative to preserve muscle mass, limit lung 
damage, and reduce flu-associated pathologies. 
COX-2 upregulation leads to increased vasodilation, vascular permeability, cytokine release, 
leukocyte migration, and pain. Inflammation from COX-2 originates in macrophages, fibroblasts, 
and endothelial cells. Our studies have shown TNFα expression as well as mRNA expression of 
ubiquitin proteasome degradation genes were elevated and prolonged in aged mice when 
compared to young during influenza infection [5]. In combination with exaggerated and 
prolonged chemokine expression CXCR3 and CXCL10, skeletal muscle had the potential for 
increase immune cell recruitment [5]. COX-2 expression in macrophages is elevated with aging, 
which increases production of a degradation inducing and T cell suppressor protein, 
prostaglandin E2 (PGE2) [43,55,56]. Since COX-2 is elevated with infection and age-
association it contributes to age-related immune dysregulation. Infliximab treatment increased 
number of PAX7 positive cells in muscle, which were otherwise suppressed by increased TNFα 
expression [51]. These data give us a potential molecular link between influenza infection and 
disability. Changes in gene expression come from mechanism(s) which we hypothesize arise 
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from exaggerated and prolonged flu-induced inflammation, which skeletal muscle is sensitive to 
and begins to breakdown. Data supports that TNFα-/- mice were able to survive and clear 
influenza without problem [57] and that acute in vivo administration of TNFα has been shown to 
impair amino acid uptake by muscle [58]. The blockade of TNFα with infliximab does not impair 
plasma cell differentiation [59] and has shown faster decline of viral titers in patients [46]. 
Altogether, these data support the use of biochemical intervention with the goal of potential 
therapies for the elderly to alleviate their influenza-induced ailment/decline. 
Preliminary data [43] reveals age-associated increase in skeletal muscle COX-2 expression. In 
the event that that neither treatment is effective, we can assume that adding the drugs may 
have triggered other compensatory cytokine/chemokine pathways that might be mechanistically 
driving the breakdown of muscle fibers. It is possible that inhibition of TNFα and COX-2 needs 
to be administered locally to the site of infection (lung) by intranasal inoculation to reduce the 
flu-induced pathology [61]. There is an increased risk when blockading TNFα for secondary 
bacterial infection and less effective vaccination through T-cell mediated pathways. While this is 
not a concern for mice in our clean facility, it is very dangerous for elderly human populations, 
which is why it is advised to vaccinate for influenza and pneumonia before undergoing treatment 
for assurance of better vaccination [53]. A more dangerous result deals with the supply and 
demand for amino acids and energy to fight the infection. If the drugs work “too well”, it will stop 
the flow of “rescue” amino acids from the skeletal muscle and there is no supply of amino acids 
to the lungs for repairing flu-damage, as well as less energy/resources for the immune 
response. In this circumstance, we would characterize which pathways are essential and cannot 
be stopped during the course of infection through process of elimination; but raises the question 
that if we supplied an additional source of amino acids (not from the skeletal muscle) if the 
problem would be remedied. An alternative to these therapies would be combining lower dose 
treatment of both anti-TNFα and COX-2 inhibition to block multiple pathways, but less 
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aggressively to reduce the observed exaggerated inflammation to average levels. The point of 
these experiments is to preserve muscle mass and maintain functionality in aging throughout 
infection. This is a critical step forward because these mechanisms could generate pointed 
therapies and development of preventative measures to ensure the maintenance of elderly 
muscle strength and function. 
In summary, we have identified many pathways and genes changing during the response to flu, 
which illuminate potential mechanisms of aged skeletal muscle atrophy, disability, and impaired 
recovery. Overlapping genes in pathways, denoted as hub genes, can be considered potential 
mechanisms for flu-induced muscle atrophy and degradation. We identified a list of such genes, 
which serve as the potential future hypotheses for causality of skeletal muscle atrophy and 
degradation as well as hypotheses for the lingering effects in aged muscle (Table 2). These 
genes focus on several key aspects of skeletal muscle health and regeneration and are vital to 
finding therapeutic strategies for combating muscle disability and degradation in aging. We 
demonstrated the presence of T cell leukocytes in aged skeletal muscle, which are potentially 
responsible for inflammation, fibrosis, and even denervation in GO pathway analyses. Our 
proposed future experiments aim to target chemotaxis of inflammatory cells, directly inhibit 
inflammatory factors such as IFN-γ and TNF-α, and bolster protection of aged skeletal muscle. 
The studies in this thesis are the first to examine in depth how flu impacts skeletal muscle with 
aging and leads to muscle dysfunction and disability. While many questions remain, this 
research has laid the ground work for others to test pathways/genes as mechanism(s) of flu-
induced muscle atrophy with aging as the first step of developing prevention and treatment 
options. Indeed, development of prophylactic and therapeutic treatments for flu-induced 
myopathies could save lives of countless older adults, prevent catastrophic disability, and 
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Table 2. Target genes for future hypothesis testing 
Gene Ensemble ID Brief Description Interpretation of Expression 
MURF-1 (TRIM63) ENSMUSG 00000028834 
tripartite motif-containing 63; 
E3 ubiquitin-protein ligase 
enzyme that upregulates during 
muscle atrophy 
major substrate is myosin 




Atrogen-1 (fbxo32) ENSMUSG 00000116076 
F-box protein 32; one of the 
four subunits of the ubiquitin 
protein ligase complex, which 
is highly expressed during 
muscle atrophy 
its upregulation signifies that 
skeletal muscle is undergoing 
atrophy 
UBB ENSMUSG 00000019505 
ubiquitin-B; targets cellular 
proteins for degradation 
upregulation indicates skeletal 
muscle is atrophying and 
degrading internal proteins via 
proteasome 
UBC ENSMUSG 00000008348 
ubiquitin-C; associated with 
protein degradation, DNA 
repair, cell cycle regulation, 
kinase modification, 
endocytosis, and regulation of 
other cell pathways 
upregulation indicates skeletal 
muscle is atrophying and 
degrading internal proteins via 
proteasome 
NLRP3 ENSMUSG 00000032691 
NLR family, pyrin domain 
containing 3; signals 
downstream to NF-κB and 
plays a role in regulating 
inflammation and apoptosis 
Downregulated by ApoD; 
NLRP3 inflammasome plays 
role in muscle inflammation; 
potentially activated by RNA 
viral particles 
CCR2 ENSMUSG 00000049103 
chemokine (C-C motif) receptor 
2; expressed on Th1 cells, 
Th17 cells, macrophages, and 
microglia 
Binds to CCL2(MCP-1), 
CCL7(MCP-3), CCL8, 
CCL13(MCP-4), and CCL16 
ligands 
CCR5 ENSMUSG 00000079227 
chemokine (C-C motif) receptor 
5; expressed on macrophages, 
dendritic cells, and memory T 
cells 
Binds to MIP1α, MIP1β, 
RANTES, MCP-2 ligands 
CCL2 ENSMUSG 00000035385 
chemokine (C-C motif) ligand 
2; produced primarily by 
monocytes, macrophages, and 
dendritic cells 
Chemotactic activity for 
monocytes and basophils with 
CCR2 and CCR4 receptors 
CCL5 ENSMUSG 00000035042 
chemokine (C-C motif) ligand 
5; also known as RANTES; 
produced by macrophages, 
DCs, lymphocytes, and 
endothelial cells 
Interacts with CCR3, CCR5, 
CCR1, and GPR75 
CCL6 ENSMUSG 00000018927 
chemokine (C-C motif) ligand 
6; expressed in neutrophil and 
macrophages 
CCL6 is the chemokine for 
CCR1 cells 
CCL7 ENSMUSG 00000035373 
chemokine (C-C motif) ligand 
7; also known as MCP3, 
produced by macrophages 
attracts monocytes and 
regulates macrophage function 
CCL8 ENSMUSG 00000009185 
chemokine (C-C motif) ligand 
8; also known as MCP2, and 
binds with CCR1, CCR2B, 
CCR3, and CCR5 
Chemotactic for and activates 
mast cells, eosinophils, 
basophils, monocytes, T cells, 
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and NK cells involved in 
inflammatory responses 
CCL12 ENSMUSG 00000035352 
chemokine (C-C motif) ligand 
12; known as MCP-5 
Attracts eosinophils, 
monocytes and lymphocytes 
CCL17 ENSMUSG 00000031780 
chemokine (C-C motif) ligand 
17 
Chemokine specifically binds 
and elicits chemotaxis in T cells 
and interacts with CCR4 
Aif1 ENSMUSG 00000024397 
allograft inflammatory factor 1; 
found in activated 
macrophages within 
inflammation 
responds to IFN-γ, IL-1β, and 
responsible for arterial 
thickening; decrease glucose 
secretion and impairs glucose 
elimination 
IL7r ENSMUSG 00000003882 
interleukin 7 receptor; 
expressed on T cells, B cells, 
monocytes, and dendritic cells 
responds to IL-7 
BCL3 ENSMUSG 00000053175 
B cell leukemia/lymphoma 3; 
signals through NFκB 
pro-survival and pro-
inflammatory gene expression 
in T cells 
IL-1β ENSMUSG 00000027398 
interleukin 1, beta; highly 
proinflammatory cytokine 
produced by multiple cell types, 
epithelial cells, macrophages, 
dendritic cells, and B cells 
Proinflammatory, part of the 
NLRP3 inflammasome process 
and contributes to 
pain/hypersensitivity 
IL-6 ENSMUSG 00000025746 
interleukin 6; stimulates 
satellite cell activation, can be 
secreted by macrophages in 
response to PAMPs or TLR 
activation; supports growth of B 
cells 
IL-6's role as an anti-
inflammatory myokine is 
mediated through its inhibitory 
effects on TNF-α and IL-1, and 
activation of IL-10 and IL-1ra; 
in muscle cells IL-6 triggers 
MAPK pathways 
IL-6ra ENSMUSG 00000027947 
interleukin 6 receptor, alpha; 
CD126, related to signal 
transducer for several 
cytokines including LIF, 
oncostatin M, CNTF, IL-11, IL-
27 
important to sensing 
inflammation and regulating 
response to inflammation; 
promotes survival of neurons 
and neuron outgrowth 
Sparc ENSMUSG 00000018593 
secreted acidic cysteine rich 
glycoprotein; aka Osteonectin, 
induces apoptosis, glycoprotein 
that binds calcium 
cell matrix interactions and 
collagen binding are dependent 
on Sparc 
CXCL2 ENSMUSG 00000058427 
chemokine (C-X-C motif) ligand 
2; MIP2-α, binds CXCR2 
secreted by monocytes and 
neutrophils at sites of 
inflammation 
CXCL10 ENSMUSG 00000034855 
chemokine (C-X-C motif) ligand 
10; proinflammatory conditions 
secreted by leukocytes, 
activated neutrophils, 
eosinophils, monocytes, 
epithelial cells, endothelial 
cells, stromal cells, fibroblasts, 
and keratinocytes in response 
to IFN-γ 
Binds to cells with CXCR3 and 
is a chemokine for T 
lymphocytes, NK cells, and 
pro-inflammatory cell types 
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CXCL13 ENSMUSG 00000023078 
chemokine (C-X-C motif) ligand 
13; secreted by follicular 
dendritic cells 
binds with CXCR5 and attracts 
B cells 
Col1a1 ENSMUSG 00000001506 
collagen, type I, alpha 1; fibril-
forming collagen 
cross-links result in the 
formation of very strong mature 
type 1 collagen fibers 
Col1a2 ENSMUSG 00000029661 
collagen, type I, alpha 2; fibril-
forming collagen 
cross-links result in the 
formation of very strong mature 
type 1 collagen fibers 
KLF10 ENSMUSG 00000037465 
Kruppel-like factor 10; induced 
by TGF-β  
promotes TGF-β, apoptosis, 
and related to fibrosis 
Actc1 ENSMUSG 00000068614 
actin, alpha, cardiac muscle 1; 
blood vessels and related to z-
lines of the sarcomere 
the skeletal muscle isoform is 
ACTA1, needed for growth and 
formation of muscle tissue 
Fbn2 ENSMUSG 00000024598 
fibrillin 2; elastic fibers found in 
connective tissue, secreted into 
ECM by fibroblasts 
microfibrils are composed end-
to-end polymers of fibrillin 
TLR9 ENSMUSG 00000045322 
toll-like receptor 9; expressed 
on dendritic cells, 
macrophages, NK cells, and 
more 
binds to RNA viruses or 
particles 
TNF ENSMUSG 00000024401 
tumor necrosis factor; systemic 
inflammation and involved in 
acute phase reaction, primarily 
produced by macrophages, 
CD4+ lymphocytes, NK cells, 
neutrophils, mast cells, 
eosinophils, and neurons 
causes apoptotic cell death, 
cachexia, inflammation, and 
can lead to sepsis 
UBD ENSMUSG 00000035186 ubiquitin-D 
upregulation of this gene may 
promote inflammation in 
chronic kidney disease; 26s 
proteasome degradation 
Tgtp1 ENSMUSG 00000078922 
T cell specific GTPase 1; 
involved in innate cell-
autonomous resistance to 
intracellular pathogens, 
induced by IFN-γ 
T cells responding to IFN-γ 
GBP5 ENSMUSG 00000105504 
guanylate binding protein 5; 
activator of NLRP3 
inflammasome assembly and 
has a role in innate immunity 
and inflammation 
pro-inflammatory response to 
IFN-γ and activation of the 
inflammasome 
IL4ra ENSMUSG 00000030748 
interleukin 4 receptor, alpha; 
CD124, binds to IL-4 and IL-13 
to regulate IgE antibody 
production in B cells. Promotes 
Th2 differentiation 
T/B cells/lymphocytes in the 
muscle 
IL2rg ENSMUSG 00000031304 
interleukin 2 receptor, gamma 
chain; CD132, surface of 
immature 
leukocytes/lymphocytes, 
directs the growth and 
maturation of T cells, B cells 
and NK cells 
T/B/NK cells/lymphocytes in 
the muscle; these cells kill 
viruses, make antibodies and 
help regulate immune system 
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Corol1a ENSMUSG 00000030707 
coronin, actin binding protein 
1A; actin binding protein that 
interacts with microtubules and 
is associated with phagocytosis 
leukocyte markers; this will 
denote phagocytic 
inflammatory cells in the 
skeletal muscle 
Vsig4 ENSMUSG 00000044206 
V-set and immunoglobulin 
domain containing 4; negative 
regulator of T cell responses; 
or a receptor for the C3b and 
iC3b complement components 
leukocyte markers; this 
denotes limitation and 
reduction of T cell responses 
Adam8 ENSMUSG 00000025473 
a disintegrin and 
metallopeptidase domain 8; 
membrane-anchored proteins 
related to disintegrins used in 
muscle development 
leukocyte markers; may be 
involved in neurodegeneration, 
but also muscle development 
Lgals3 ENSMUSG 00000050335 
lectin, galactose binding, 





granulocyte markers; a 
correlation between Lgals3 and 
fibrosis is found; high levels in 
cardiovascular disease; related 
to stroke 
Itgam (CD11b) ENSMUSG 00000030786 
integrin alpha M; or CD11b, 
surface marker on leukocytes 
involved in innate immune 
system mediating inflammation 




cytotoxicity, chemotaxis, and 
cellular activation of 
inflammatory leukocytes 
Fcgr3 ENSMUSG 00000059498 
Fc receptor, IgG, low affinity III; 
neutrophil marker and Fc 
receptor 
granulocyte markers; denotes 
neutrophil activity 
Mstn ENSMUSG 00000026100 
myostatin; GDF-8; produced 
and released by myocytes that 
act on muscle cells' autocrine 
function to inhibit myogenesis 
Associated with muscle 
wasting, muscular dystrophy, 
and muscle hypertrophy 
through Akt inhibition 
Ddit4 ENSMUSG 00000020108 
DNA-damage-inducible 
transcript 4; negative regulator 
of mTOR involved in 
autophagy, upregulated in 
response to hypoxia DNA 
damage, or energy stress 
Response to virus; this is a pro-
autophagy response to 
damage in the cell 
Nlrc5 ENSMUSG 00000074151 
NLR family, CARD domain 
containing 5; innate immunity 
to viruses and potentially by 
regulating interferon activity 
Response to virus in T, NK, 
and NKT lymphocytes; pro-
inflammatory & inflammasome 
activity 
Rnf216 ENSMUSG 00000045078 
E3 ubiquitin-protein ligase ring 
finger protein 216 interacts with 
serine/threonine protein kinase, 
receptor-interacting protein. 
Attaches ubiquitin  
Response to virus with 
proteasome activity and 
ubiquitination of cell 
components, inhibition of TNF 
and IL1 induced NFκB 
activation 
F7 ENSMUSG 00000031443 
coagulation factor VII; one of 
the proteins that causes blood 
to clot in the coagulation 
cascade 





Mymk ENSMUSG 00000009214 
myomaker, myoblast fusion 
factor; positive regulation of 
skeletal muscle hypertrophy, 
myoblast fusion involved in 
skeletal muscle regeneration 
positive regulator of skeletal 
muscle regeneration/myo-
differentiation 
Mustn1 ENSMUSG 00000042485 
musculoskeletal, embryonic 
nuclear protein 1; involved in 
wound healing, tissue 
regeneration 
pan-musculoskeletal cell 
marker and regulatory gene in 
myogenic and chondrogenic 
lineages 
Mki67 ENSMUSG 00000031004 
antigen identified by 
monoclonal antibody Ki 67; 
evidence of cell proliferation 
seen in regeneration/myo-
differentiation 
ApoD ENSMUSG 00000022548 
apolipoprotein D; associated 
with neurological nerve injury 
especially related to myelin 
sheath 
involved in pathways for 
regeneration/myo-
differentiation 
Cdk1 ENSMUSG 00000019942 
cyclin-dependent kinase 1 
functions as serine/threosine 





MyoG ENSMUSG 00000026459 
myogenin; muscle specific 
basic helix loop helix 
transcription factor involved in 
the coordination of skeletal 
muscle development, 
myogenesis, and repair 
centric in the 
regeneration/myo-
differentiation of skeletal 
muscle 
Fn1  ENSMUSG 00000026193 
fibronectin 1 binds ECM 
proteins such as collagen, 
fibrin, and heparan sulfate 
proteoglycans 
Altered fibronectin expression, 
degradation, and organization 
is associated with pathologies 
like fibrosis and cachexia 
SYT9 ENSMUSG 00000062542 
synaptotagmin IX; involved in 
Ca2+ dependent exocytosis of 
secretory vesicles through 
Ca2+ and phospholipid binding 
to the C2 domain 
Neuron/axon/synapse 
pathways of neuromuscular 
junction 
Ache ENSMUSG 00000023328 
acetylcholinesterase; 
terminates signal transduction 
at the neuromuscular junction 
by rapid hydrolysis of the 
acetylcholine released into the 
synaptic cleft 
Neuron/axon/synapse at the 
neuromuscular junction; 
inhibition of AChE leads to 
accumulation of Ach in the 










The immune system has many intricate pieces that come together like an elegant mosaic. When 
all of the parts are fully operative, the system functions properly, protecting the host from 
disease. When one of the pieces malfunctions, compensatory mechanisms can often overcome 
the deficit. Occasionally, this is not the case and a singular problem can cause cascading 
downstream effects. In the case of the aged immune system, with many broken or declining 
parts, it becomes incredibly difficult to follow which are the mediators of the problem and which 
are simply the downstream consequence. Only by increasing our understanding of what 
changes are occurring in the aged immune system we can begin to dissect causality and 
consequences. This thesis, though primarily descriptive in nature, progresses our understanding 
of the aged immune system at the intersection of skeletal muscle biology and influenza 
infection. 
We used C57BL/6 mice as our widely accepted biomedical research model of aging. Inbred 
laboratory mice have a much shorter lifespan of about 24 months [1] compared to the average 
United States citizen at 78.8 years [2]. Mice reach sexual maturity and are analogous to human 
adults around 8-12 weeks of age [3]. Mice are considered aged or “older adults” starting at 
roughly 18 months [4]. One problem that is becoming more widely considered and published in 
the immunology community with the laboratory mouse model is cleanliness and exposure to 
environmental antigens [5]. Our laboratory mice live in specific pathogen free (SPF) conditions 
and are thusly kept from pathogen exposure until purposeful experimental introduction. The lack 
of exposure to specific pathogens has been shown to alter the formation and function of the 
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immune system, which puts into question the comparability of SPF mice to human immune 
systems [6]. Chronic pathogens like cytomegalovirus (CMV) dramatically alter the immune 
system and are completely neglected in SPF mouse models while 50% of U.S. adults have 
CMV [7]. Currently, several groups are working to create mouse pathogen exposure cocktails 
and models to more adequately represent the human immune system [5, 6, 8]. These models 
could potentially be applied to the aging mouse model to enhance its clinical relevance. 
The C57BL/6 mouse model is a powerful immunological tool because of the MHC Class I and 
Class II reagents and T cell receptor transgenic strains available to examine antigen-specific T 
cell responses [9], but it lacks genetic diversity. To overcome inbred models and recapitulate 
human genetic diversity, other mouse models can be employed such as diversity outbred mice, 
collaborative cross mice, and four-way cross mice [10-12]. Several of these are currently used 
in models of aging systems [4, 10] and collaborative cross mice were successfully used in a 
sequencing experiment to determine genetic variance of survival genes with Ebola virus [13]. 
Despite the shortcomings of inbred mouse models such as the C57BL/6 strain used pervasively 
in this thesis, it represents a widely accepted methodology and good starting point for studying 
the aged immune system. More complex models require further validation and development of 
reagents before they can become as useful tools for scientific studies. 
We live in an aging world, where the burden on world healthcare is increasing rapidly with the 
increases in the vulnerable aging population. Older adults make up 90% of flu-related deaths 
and are at increased risk of both progressive and catastrophic disability following flu infection 
[14, 15, 16]. With these clinical needs in mind and the aforementioned models above, we set out 
to investigate the molecular mechanism of flu-induced muscle degradation and disability. In 
chapter two of this thesis, we established the molecular link between pulmonary infection and 
skeletal muscle. Equally important, we provided evidence that influenza RNA could not be 
detected in skeletal muscle via PCR nor were primary myoblasts from young or aged mice able 
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to be infected with our A/PR/8/34 (PR8) influenza virus in vitro [17]. In summary, this chapter 
was the first to identify in a controlled experimental setting flu-induced muscle inflammation and 
atrophy alongside functional impairment. We have demonstrated that key inflammatory signals, 
and key ubiquitin proteasome components, both atrogin1 and MuRF1, as well as ubiquitin B and 
ubiquitin C, are upregulated. As it is known that muscle repair is diminished with aging, it is 
likely these muscle losses are not easily recoverable. Thus, laying the ground work for the next 
portion of my thesis project to target these pathways to prevent flu-induced atrophy and 
potential loss of quality of life in older adults. 
The aim of chapter three was to determine if prior immunity reduces flu-induced skeletal muscle 
decrements. We demonstrated that prior non-neutralizing immunity, induced by vaccination with 
recombinant influenza nucleoprotein, prevents flu-induced muscle fast twitch fiber atrophy and 
consequently protects muscle functionality. We also determined that vaccine-induced protection 
is not mediated by antibody; however, more research is necessary to determine if protection is 
solely mediated via a T cell dependent mechanism. As disability is one of the major 
complications of flu infection in older adults, the goal of this study was to determine if prior non-
neutralizing immunity could provide protection to skeletal muscle. We determined that 
vaccination indeed could prevent or reduce muscle decrements due to flu infection despite 
reduced vaccine efficacy with aging. Thus, flu vaccination is still an essential part of protecting 
older adults from flu-induced disability. Chapter three expanded on chapter two’s discoveries in 
that similar parameters were tested with regard to muscle function, cytokine secretion, and 
muscle gene expression, but added in additional facets of immunohistochemistry. The 
immunohistochemistry highlighted the vulnerability of MyHC IIB fibers to inflammation during flu, 
especially in aging. Evidence confirms many inflammatory factors such as TNF-α receptor-
mediated apoptotic events increase with age, especially in type II fiber-containing muscles [18]. 
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This significant loss in fast twitch muscle fibers pointed to a measurable, functional and 
molecular change that can be targeted for therapeutic intervention. 
Although the mechanism of influenza-induced myopathy is still to be determined, the research in 
this thesis has significantly progressed our understanding of many aspects of skeletal muscle 
decrement. We first determined that despite lack of direct flu infection, skeletal muscle still 
experienced atrophic gene expression which was prolonged and heightened in aged mice in 
chapter two. We determined, in chapter three, that the muscle specific atrophy observed in 
chapter two occurred primarily in MyHC type IIB muscle fibers. To complement this data, we 
confirmed that aged muscle had fibrosis formations at 9 DPI (via trichrome stain) and that aged 
muscle H&E’s revealed increased nuclei and architectural disruption across infection. These 
findings supported the hypothesis that the mechanism of muscle decrement could be from 
inflammatory cellular infiltration, which remains prolonged and elevated in aged mice. Further 
confirmation of this hypothesis came from our pathway analysis of skeletal muscle mRNA-
Sequencing in chapter four, which highlighted chemotaxis of inflammatory cell types, activation 
of inflammatory cells, and secretory pathways specific to catabolic/inflammatory processes. 
These transcriptomic profiles were verified with immunofluorescence in young and aged skeletal 
muscle. We determined and quantified the presence of skeletal muscle T cells (CD3+ CD45+ 
Lyve1- CD31-) and leukocytes/lymphocytes (CD3- CD45+ Lyve1- CD31-), which showed that 
the only increases in these cell populations was in aged mice later in infection (11 and 15 DPI). 
This occurred concomitantly with disrupted architecture, fibrosis, and increased nuclei in aged 
muscle IHC staining. Taken together, there is much support for the theory that inflammatory cell 
types in the aged muscle are pervasively secreting inflammatory factors, which lead to more 
muscle damage and prevent the regeneration of aged muscle, and perpetuate the fibrosis and 
ECM dysregulation observed in our findings. 
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More experiments are necessary to determine functionally active cell populations within the 
skeletal muscle tissue. Other groups have attempted to identify new populations of cells in 
skeletal muscle via flow cytometry [19, 20], but this method is restricted by how many markers 
are used and biased by what markers are selected. Indeed, the best approach would be to use 
single cell RNA-sequencing of skeletal muscle tissue and cellular composition [21], which would 
result in infinitely more information. Neutrophils and macrophages are normally seen traversing 
inflamed skeletal muscle as a means of clearing debris and maintenance, but even regulatory T 
cell populations have been sited controlling inflammation [22]. Immune cell infiltration of muscle, 
despite lack of direct infection, occurs during flu infection because of the increase of chemotaxis 
receptors which attract/summon cells to the tissue [23, 24, 25, 26]. Muscle is particularly 
“sensitive” to changes in body homeostasis and it is known to secrete inflammatory mediators 
after exercise for repair/energy replenishment and is especially reactive to serum mediated 
inflammatory signaling [15, 17, 27, 28, 29, 30, 31]. This sensitivity may be an evolutionary 
mechanism for the release of amino acids from muscle breakdown to aid in reparation efforts 
elsewhere in the body. In fact, we hypothesize that influenza-induced weight loss is primarily 
due to skeletal muscle atrophy, but this was not confirmed via NMR/DEXA/MRI. The exact 
mechanisms involved are still unknown, however the morphological and molecular changes in 
muscle are evidence that mechanism(s) of cell infiltration, systemic inflammation, and/or flu-
induced inflammation from lung infection [17, 24, 32, 33, 34].  
Healthy aging is associated with an increased basal rate of muscle protein synthesis in women 
compared to men, and resistance to the anabolic effect of nutritional stimuli in both sexes [32]. 
There is sexual dimorphism in age-related skeletal muscle protein synthesis and metabolism 
responsible for age-related decline in muscle mass, which leaves women at a greater risk of 
disability than men. Average percent of muscle mass lost between the ages of 70 (W: 22%, M: 
15%) and 90 (W: 81%, M: 57%) is much greater for women [35]. From an immunological 
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standpoint, women have more robust inflammatory responses to illness than men, but develop 
better antibody titers and long-term protection [36]. It is important to examine the sex-
differences and model them appropriately, however, since we are still trying to discover the 
underlying mechanisms and pathways involved, we have matched our previous experiments 
and continued our research on male mice. It is well documented that there are sex differences 
in muscle responses to unloading [33, 37, 38] and hypertrophy [39, 40] and exercise-induced 
muscle damage [24, 41, 42]. These are likely due to endocrine differences, such as 
testosterone and estrogen, molecular signaling changes [32, 43] and other sex-related 
differences [34]. Clinically, sex differences in physical function and disability exist with aging, 
with higher disability rates in women [35, 44, 45]. Thus, the first set of transcriptomic analyses 
were performed on male mice for this thesis. Further experiments in the Haynes laboratory will 
be performed in female mice to determine relevant sex differences. This will be particularly 
useful to gain understanding of translationally relevant and clinically meaningful differences in 
resiliency and susceptibility to disability between sexes with aging. 
The studies in this thesis are the first to examine in depth how influenza induces skeletal muscle 
degradation in aging, but many questions remain to be answered. Since skeletal muscle is still 
beginning to be appreciated for the role it plays in immune responses, it is not surprising that 
many aspects of myokines, muscle biology, and amino acid storage remain to be elucidated. 
This research has laid the ground work for others to further characterize and test 
pathways/genes as mechanism(s) of flu induced muscle degradation and dysfunction in aging. 
The findings in chapter 4 present multiple targets that could be used to enhance and protect 
skeletal muscle in older adults. This research has significantly progressed our understanding of 
the aged immune response to flu-induced myopathy. This thesis has contributed to our 
understanding of how specific fiber-types are more prone to atrophy during infection and how 
vaccination prevents protects aged muscle from this ailment. Foundationally, these studies have 
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culminated into a hypothesis generating transcriptomic project, which has painted a fully 
unbiased look into aged muscle processes during flu infection. The work following this thesis 
has the potential to develop future treatments that could help save lives of countless older 
adults and prevent catastrophic disability.  
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